Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~August 4,~~November 3, 2017, Medical Properties Trust, Inc. had ~~364,083,580~~364,156,080 shares of common stock, par value $0.001, outstanding.

This report combines the Quarterly Reports on Form10-Q for the three and ~~six~~nine months ended ~~June~~September 30, 2017, of Medical Properties Trust, Inc., a Maryland corporation, and MPT Operating Partnership, L.P., a Delaware limited partnership, through which Medical Properties Trust, Inc. conducts substantially all of its operations. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” “our company,” “Medical Properties,” “MPT,” or “the company” refer to Medical Properties Trust, Inc. together with its consolidated subsidiaries, including MPT Operating Partnership, L.P. Unless otherwise indicated or unless the context requires otherwise, all references to “our operating partnership” or “the operating partnership” refer to MPT Operating Partnership, L.P. together with its consolidated subsidiaries.


	June 30, 2017			December 31, 2016			September 30, 2017			December 31, 2016
(In thousands, except per share amounts)	(Unaudited)			(Note 2)			(Unaudited)			(Note 2)
Assets
Real estate assets
Land, buildings and improvements, intangible lease assets, and other	$	4,976,129		$	4,317,866		$	5,795,286		$	4,317,866
Mortgage loans		1,062,558			1,060,400			1,777,555			1,060,400
Net investment in direct financing leases		693,243			648,102			695,829			648,102

Gross investment in real estate assets		6,731,930			6,026,368			8,268,670			6,026,368
Accumulated depreciation and amortization		(384,826	)		(325,125	)		(418,880	)		(325,125	)

Net investment in real estate assets		6,347,104			5,701,243			7,849,790			5,701,243
Cash and cash equivalents		236,364			83,240			188,224			83,240
Interest and rent receivables		68,537			57,698			105,817			57,698
Straight-line rent receivables		147,755			116,861			166,142			116,861
Other loans		152,968			155,721			151,709			155,721
Other assets		375,109			303,773			465,358			303,773

Total Assets	$	7,327,837		$	6,418,536		$	8,927,040		$	6,418,536

Liabilities and Equity
Liabilities
Debt, net	$	3,221,054		$	2,909,341		$	4,832,264		$	2,909,341
Accounts payable and accrued expenses		219,527			207,711			180,631			207,711
Deferred revenue		20,108			19,933			18,906			19,933
Lease deposits and other obligations to tenants		34,943			28,323			54,035			28,323

Total Liabilities		3,495,632			3,165,308			5,085,836			3,165,308
Equity
Preferred stock, $0.001 par value. Authorized 10,000 shares; no shares outstanding		—			—			—			—
Common stock, $0.001 par value. Authorized 500,000 shares; issued and outstanding — 364,020 shares at June 30, 2017 and 320,514 shares at December 31, 2016		364			321
Common stock, $0.001 par value. Authorized 500,000 shares; issued and outstanding — 364,084 shares at September 30, 2017 and 320,514 shares at December 31, 2016								364			321
Additional paid in capital		4,327,733			3,775,336			4,330,495			3,775,336
Distributions in excess of net income		(457,419	)		(434,114	)		(468,473	)		(434,114	)
Accumulated other comprehensive loss		(52,591	)		(92,903	)		(35,165	)		(92,903	)
Treasury shares, at cost		(777	)		(262	)		(777	)		(262	)

Total Medical Properties Trust, Inc. Stockholders’ Equity		3,817,310			3,248,378			3,826,444			3,248,378
Non-controlling interests		14,895			4,850			14,760			4,850

Total Equity		3,832,205			3,253,228			3,841,204			3,253,228

Total Liabilities and Equity	$	7,327,837		$	6,418,536		$	8,927,040		$	6,418,536


	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In thousands, except per share amounts)	2017			2016			2017			2016			2017			2016			2017			2016
Revenues
Rent billed	$	103,447		$	77,960		$	200,210		$	152,021		$	110,930		$	82,387		$	311,140		$	234,408
Straight-line rent		16,277			8,551			29,056			16,768			17,505			9,741			46,561			26,509
Income from direct financing leases		18,312			13,552			36,192			32,503			19,115			14,678			55,307			47,181
Interest and fee income		28,771			26,237			57,746			60,007			29,030			19,749			86,776			79,756

Total revenues		166,807			126,300			323,204			261,299			176,580			126,555			499,784			387,854
Expenses
Real estate depreciation and amortization		29,493			22,832			57,079			43,974			31,915			23,876			88,994			67,850
Impairment charges		—			7,375			—			7,375			—			(80	)		—			7,295
Property-related		1,153			784			2,481			1,685			1,519			(93	)		4,000			1,592
Acquisition expenses		10,806			4,767			13,562			3,702			7,434			2,677			20,996			6,379
General and administrative		15,079			12,045			28,276			23,516			15,011			12,305			43,287			35,821

Total operating expenses		56,531			47,803			101,398			80,252			55,879			38,685			157,277			118,937

Operating income		110,276			78,497			221,806			181,047			120,701			87,870			342,507			268,917
Other income (expense)
Interest expense		(39,710	)		(41,501	)		(77,739	)		(80,870	)		(42,759	)		(40,262	)		(120,498	)		(121,132	)
Gain on sale of real estate and other asset dispositions, net		—			16,638			7,413			16,678			18			44,616			7,431			61,294
Earnings (loss) from equity and other interests		2,800			1,200			4,514			(3,801	)		3,384			1,245			7,898			(2,556	)
Unutilized financing fees/debt refinancing costs		(751	)		—			(14,380	)		(4	)		(4,414	)		(22,535	)		(18,794	)		(22,539	)
Other income (expense)		567			(546	)		620			(217	)		481			99			1,101			(118	)
Income tax benefit (expense)		614			(364	)		(253	)		(683	)
Income tax expense														(530	)		(490	)		(783	)		(1,173	)

Net other expense		(36,480	)		(24,573	)		(79,825	)		(68,897	)		(43,820	)		(17,327	)		(123,645	)		(86,224	)

Income from continuing operations		73,796			53,924			141,981			112,150			76,881			70,543			218,862			182,693
Loss from discontinued operations		—			—			—			(1	)		—			—			—			(1	)

Net income		73,796			53,924			141,981			112,149			76,881			70,543			218,862			182,692
Net income attributable tonon-controlling interests		(381	)		(200	)		(596	)		(498	)		(417	)		(185	)		(1,013	)		(683	)

Net income attributable to MPT common stockholders	$	73,415		$	53,724		$	141,385		$	111,651		$	76,464		$	70,358		$	217,849		$	182,009

Earnings per common share — basic
Income from continuing operations attributable to MPT common stockholders	$	0.21		$	0.23		$	0.42		$	0.47		$	0.21		$	0.29		$	0.63		$	0.75
Loss from discontinued operations attributable to MPT common stockholders		—			—			—			—			—			—			—			—

Net income attributable to MPT common stockholders	$	0.21		$	0.23		$	0.42		$	0.47		$	0.21		$	0.29		$	0.63		$	0.75

Weighted average shares outstanding — basic		349,856			238,082			335,456			237,796			364,315			246,230			345,076			240,607

Earnings per common share — diluted
Income from continuing operations attributable to MPT common stockholders	$	0.21		$	0.22		$	0.42		$	0.47		$	0.21		$	0.28		$	0.63		$	0.75
Loss from discontinued operations attributable to MPT common stockholders		—			—			—			—			—			—			—			—

Net income attributable to MPT common stockholders	$	0.21		$	0.22		$	0.42		$	0.47		$	0.21		$	0.28		$	0.63		$	0.75

Weighted average shares outstanding — diluted		350,319			239,008			335,871			238,413			365,046			247,468			345,596			241,432

Dividends declared per common share	$	0.24		$	0.23		$	0.48		$	0.45		$	0.24		$	0.23		$	0.72		$	0.68


	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In thousands)	2017			2016			2017			2016			2017			2016			2017			2016
Net income	$	73,796		$	53,924		$	141,981		$	112,149		$	76,881		$	70,543		$	218,862		$	182,692
Other comprehensive income:
Unrealized gain on interest rate swap		—			825			—			1,640			—			854			—			2,494
Foreign currency translation gain (loss)		34,020			(14,683	)		40,312			5,904
Foreign currency translation gain														17,426			4,450			57,738			10,354

Total comprehensive income		107,816			40,066			182,293			119,693			94,307			75,847			276,600			195,540
Comprehensive income attributable tonon-controlling interests		(381	)		(200	)		(596	)		(498	)		(417	)		(185	)		(1,013	)		(683	)

Comprehensive income attributable to MPT common stockholders	$	107,435		$	39,866		$	181,697		$	119,195		$	93,890		$	75,662		$	275,587		$	194,857


	For the Six Months Ended June 30,						For the Nine Months Ended September 30,
(In thousands)	2017			2016			2017			2016
Operating activities
Net income	$	141,981		$	112,149		$	218,862		$	182,692
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		59,825			45,170			93,805			69,720
Amortization of deferred financing costs and debt discount		3,139			3,893			4,748			5,799
Direct financing lease interest accretion		(4,690	)		(4,766	)		(7,276	)		(6,757	)
Straight-line rent revenue		(30,173	)		(17,268	)		(47,678	)		(27,009	)
Share-based compensation		4,377			4,152			7,148			5,832
Gain from sale of real estate and other asset dispositions, net		(7,413	)		(16,678	)		(7,431	)		(61,294	)
Impairment charges		—			7,375			—			7,295
Straight-line rent and otherwrite-off		1,117			3,063			1,117			3,063
Unutilized financing fees/debt refinancing costs		14,380			4			18,794			22,539
Other adjustments		(5,747	)		(6,605	)		(7,152	)		(8,398	)
Changes in:
Interest and rent receivables		(10,786	)		(2,743	)		(14,613	)		(12,790	)
Accounts payable and accrued expenses		(11,126	)		9,544			(40,378	)		(12,403	)

Net cash provided by operating activities		154,884			137,290			219,946			168,289
Investing activities
Cash paid for acquisitions and other related investments		(600,781	)		(109,991	)		(2,152,069	)		(213,100	)
Net proceeds from sale of real estate		64,335			89,165			64,362			198,767
Principal received on loans receivable		5,188			705,501			6,760			804,809
Investment in loans receivable		(3,574	)		(96,504	)		(18,574	)		(102,909	)
Construction in progress and other		(36,002	)		(101,113	)		(52,953	)		(139,336	)
Investment in unsecured senior notes		—			(50,000	)		—			(50,000	)
Proceeds from sale of unsecured senior notes		—			50,000			—			50,000
Other investments, net		(67,101	)		(6,952	)		(73,982	)		(52,701	)

Net cash (used for) provided by investing activities		(637,935	)		480,106			(2,226,456	)		495,530
Financing activities
Proceeds from term debt		955,280			500,000			2,355,280			1,000,000
Payments of term debt		(675,279	)		(147	)		(688,221	)		(515,221	)
Revolving credit facilities, net		(39,911	)		(1,075,000	)		155,089			(1,100,000	)
Distributions paid		(151,692	)		(104,788	)		(239,211	)		(160,060	)
Lease deposits and other obligations to tenants		6,669			9,593			(7,467	)		13,784
Proceeds from sale of common shares, net of offering costs		548,063			44,306			548,055			1,024,088
Debt issuance costs paid and other financing activities		(16,543	)		(8,465	)		(27,167	)		(31,317	)

Net cash provided by (used for) financing activities		626,587			(634,501	)
Net cash provided by financing activities								2,096,358			231,274

Increase (decrease) in cash and cash equivalents for period		143,536			(17,105	)
Increase in cash and cash equivalents for period								89,848			895,093
Effect of exchange rate changes		9,588			3,125			15,136			4,283
Cash and cash equivalents at beginning of period		83,240			195,541			83,240			195,541

Cash and cash equivalents at end of period	$	236,364		$	181,561		$	188,224		$	1,094,917

Interest paid	$	63,371		$	57,118		$	131,708		$	120,374
Supplemental schedule of non-cash investing activities:
(Decrease) increase in development project construction costs incurred, not paid							$	(9,036	)	$	17,458
Supplemental schedule ofnon-cash financing activities:
Distributions declared, unpaid	$	87,519		$	55,272
Distributions declared, not paid							$	87,519		$	58,333


	June 30, 2017			December 31, 2016			September 30, 2017			December 31, 2016
(In thousands)	(Unaudited)			(Note 2)			(Unaudited)			(Note 2)
Assets
Real estate assets
Land, buildings and improvements, intangible lease assets, and other	$	4,976,129		$	4,317,866		$	5,795,286		$	4,317,866
Mortgage loans		1,062,558			1,060,400			1,777,555			1,060,400
Net investment in direct financing leases		693,243			648,102			695,829			648,102

Gross investment in real estate assets		6,731,930			6,026,368			8,268,670			6,026,368
Accumulated depreciation and amortization		(384,826	)		(325,125	)		(418,880	)		(325,125	)

Net investment in real estate assets		6,347,104			5,701,243			7,849,790			5,701,243
Cash and cash equivalents		236,364			83,240			188,224			83,240
Interest and rent receivables		68,537			57,698			105,817			57,698
Straight-line rent receivables		147,755			116,861			166,142			116,861
Other loans		152,968			155,721			151,709			155,721
Other assets		375,109			303,773			465,358			303,773

Total Assets	$	7,327,837		$	6,418,536		$	8,927,040		$	6,418,536

Liabilities and Capital
Liabilities
Debt, net	$	3,221,054		$	2,909,341		$	4,832,264		$	2,909,341
Accounts payable and accrued expenses		131,599			132,868			92,793			132,868
Deferred revenue		20,108			19,933			18,906			19,933
Lease deposits and other obligations to tenants		34,943			28,323			54,035			28,323
Payable due to Medical Properties Trust, Inc.		87,538			74,453			87,448			74,453

Total Liabilities		3,495,242			3,164,918			5,085,446			3,164,918
Capital
General Partner — issued and outstanding — 3,640 units at June 30, 2017 and 3,204 units at December 31, 2016		38,722			33,436
General Partner — issued and outstanding — 3,641 units at September 30, 2017 and 3,204 units at December 31, 2016								38,639			33,436
Limited Partners:
Common units — issued and outstanding — 360,380 units at June 30, 2017 and 317,310 units at December 31, 2016		3,831,569			3,308,235
LTIP units — issued and outstanding — 292 units at June 30, 2017 and December 31, 2016		—			—
Common units — issued and outstanding — 360,443 units at September 30, 2017 and 317,310 units at December 31, 2016								3,823,360			3,308,235
LTIP units — issued and outstanding — 292 units at September 30, 2017 and December 31, 2016								—			—
Accumulated other comprehensive loss		(52,591	)		(92,903	)		(35,165	)		(92,903	)

Total MPT Operating Partnership, L.P. Capital		3,817,700			3,248,768			3,826,834			3,248,768
Non-controlling interests		14,895			4,850			14,760			4,850

Total Capital		3,832,595			3,253,618			3,841,594			3,253,618

Total Liabilities and Capital	$	7,327,837		$	6,418,536		$	8,927,040		$	6,418,536


	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In thousands, except per unit amounts)	2017			2016			2017			2016			2017			2016			2017			2016
Revenues
Rent billed	$	103,447		$	77,960		$	200,210		$	152,021		$	110,930		$	82,387		$	311,140		$	234,408
Straight-line rent		16,277			8,551			29,056			16,768			17,505			9,741			46,561			26,509
Income from direct financing leases		18,312			13,552			36,192			32,503			19,115			14,678			55,307			47,181
Interest and fee income		28,771			26,237			57,746			60,007			29,030			19,749			86,776			79,756

Total revenues		166,807			126,300			323,204			261,299			176,580			126,555			499,784			387,854
Expenses
Real estate depreciation and amortization		29,493			22,832			57,079			43,974			31,915			23,876			88,994			67,850
Impairment charges		—			7,375			—			7,375			—			(80	)		—			7,295
Property-related		1,153			784			2,481			1,685			1,519			(93	)		4,000			1,592
Acquisition expenses		10,806			4,767			13,562			3,702			7,434			2,677			20,996			6,379
General and administrative		15,079			12,045			28,276			23,516			15,011			12,305			43,287			35,821

Total operating expenses		56,531			47,803			101,398			80,252			55,879			38,685			157,277			118,937

Operating income		110,276			78,497			221,806			181,047			120,701			87,870			342,507			268,917
Other income (expense)
Interest expense		(39,710	)		(41,501	)		(77,739	)		(80,870	)		(42,759	)		(40,262	)		(120,498	)		(121,132	)
Gain on sale of real estate and other asset dispositions, net		—			16,638			7,413			16,678			18			44,616			7,431			61,294
Earnings (loss) from equity and other interests		2,800			1,200			4,514			(3,801	)		3,384			1,245			7,898			(2,556	)
Unutilized financing fees/debt refinancing costs		(751	)		—			(14,380	)		(4	)		(4,414	)		(22,535	)		(18,794	)		(22,539	)
Other income (expense)		567			(546	)		620			(217	)		481			99			1,101			(118	)
Income tax benefit (expense)		614			(364	)		(253	)		(683	)
Income tax expense														(530	)		(490	)		(783	)		(1,173	)

Net other expense		(36,480	)		(24,573	)		(79,825	)		(68,897	)		(43,820	)		(17,327	)		(123,645	)		(86,224	)

Income from continuing operations		73,796			53,924			141,981			112,150			76,881			70,543			218,862			182,693
Loss from discontinued operations		—			—			—			(1	)		—			—			—			(1	)

Net income		73,796			53,924			141,981			112,149			76,881			70,543			218,862			182,692
Net income attributable tonon-controlling interests		(381	)		(200	)		(596	)		(498	)		(417	)		(185	)		(1,013	)		(683	)

Net income attributable to MPT Operating Partnership partners	$	73,415		$	53,724		$	141,385		$	111,651		$	76,464		$	70,358		$	217,849		$	182,009

Earnings per unit — basic
Income from continuing operations attributable to MPT Operating Partnership partners	$	0.21		$	0.23		$	0.42		$	0.47		$	0.21		$	0.29		$	0.63		$	0.75
Loss from discontinued operations attributable to MPT Operating Partnership partners		—			—			—			—			—			—			—			—

Net income attributable to MPT Operating Partnership partners	$	0.21		$	0.23		$	0.42		$	0.47		$	0.21		$	0.29		$	0.63		$	0.75

Weighted average units outstanding — basic		349,856			238,082			335,456			237,796			364,315			246,230			345,076			240,607

Earnings per unit — diluted
Income from continuing operations attributable to MPT Operating Partnership partners	$	0.21		$	0.22		$	0.42		$	0.47		$	0.21		$	0.28		$	0.63		$	0.75
Loss from discontinued operations attributable to MPT Operating Partnership partners		—			—			—			—			—			—			—			—

Net income attributable to MPT Operating Partnership partners	$	0.21		$	0.22		$	0.42		$	0.47		$	0.21		$	0.28		$	0.63		$	0.75

Weighted average units outstanding — diluted		350,319			239,008			335,871			238,413			365,046			247,468			345,596			241,432

Dividends declared per unit	$	0.24		$	0.23		$	0.48		$	0.45		$	0.24		$	0.23		$	0.72		$	0.68


	For the Three Months Ended June 30,						For the Six Months Ended June 30,						For the Three Months Ended September 30,						For the Nine Months Ended September 30,
(In thousands)	2017			2016			2017			2016			2017			2016			2017			2016
Net income	$	73,796		$	53,924		$	141,981		$	112,149		$	76,881		$	70,543		$	218,862		$	182,692
Other comprehensive income:
Unrealized gain on interest rate swap		—			825			—			1,640			—			854			—			2,494
Foreign currency translation gain (loss)		34,020			(14,683	)		40,312			5,904
Foreign currency translation gain														17,426			4,450			57,738			10,354

Total comprehensive income		107,816			40,066			182,293			119,693			94,307			75,847			276,600			195,540
Comprehensive income attributable tonon-controlling interests		(381	)		(200	)		(596	)		(498	)		(417	)		(185	)		(1,013	)		(683	)

Comprehensive income attributable to MPT Operating Partnership Partners	$	107,435		$	39,866		$	181,697		$	119,195		$	93,890		$	75,662		$	275,587		$	194,857


	For the Six Months Ended June 30,						For the Nine Months Ended September 30,
(In thousands)	2017			2016			2017			2016
Operating activities
Net income	$	141,981		$	112,149		$	218,862		$	182,692
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		59,825			45,170			93,805			69,720
Amortization of deferred financing costs and debt discount		3,139			3,893			4,748			5,799
Direct financing lease interest accretion		(4,690	)		(4,766	)		(7,276	)		(6,757	)
Straight-line rent revenue		(30,173	)		(17,268	)		(47,678	)		(27,009	)
Unit-based compensation		4,377			4,152			7,148			5,832
Gain from sale of real estate and other asset dispositions, net		(7,413	)		(16,678	)		(7,431	)		(61,294	)
Impairment charges		—			7,375			—			7,295
Straight-line rent and otherwrite-off		1,117			3,063			1,117			3,063
Unutilized financing fees/debt refinancing costs		14,380			4			18,794			22,539
Other adjustments		(5,747	)		(6,605	)		(7,152	)		(8,398	)
Changes in:
Interest and rent receivables		(10,786	)		(2,743	)		(14,613	)		(12,790	)
Accounts payable and accrued expenses		(11,126	)		9,544			(40,378	)		(12,403	)

Net cash provided by operating activities		154,884			137,290			219,946			168,289
Investing activities
Cash paid for acquisitions and other related investments		(600,781	)		(109,991	)		(2,152,069	)		(213,100	)
Net proceeds from sale of real estate		64,335			89,165			64,362			198,767
Principal received on loans receivable		5,188			705,501			6,760			804,809
Investment in loans receivable		(3,574	)		(96,504	)		(18,574	)		(102,909	)
Construction in progress and other		(36,002	)		(101,113	)		(52,953	)		(139,336	)
Investment in unsecured senior notes		—			(50,000	)		—			(50,000	)
Proceeds from sale of unsecured senior notes		—			50,000			—			50,000
Other investments, net		(67,101	)		(6,952	)		(73,982	)		(52,701	)

Net cash (used for) provided by investing activities		(637,935	)		480,106			(2,226,456	)		495,530
Financing activities
Proceeds from term debt		955,280			500,000			2,355,280			1,000,000
Payments of term debt		(675,279	)		(147	)		(688,221	)		(515,221	)
Revolving credit facilities, net		(39,911	)		(1,075,000	)		155,089			(1,100,000	)
Distributions paid		(151,692	)		(104,788	)		(239,211	)		(160,060	)
Lease deposits and other obligations to tenants		6,669			9,593			(7,467	)		13,784
Proceeds from sale of units, net of offering costs		548,063			44,306			548,055			1,024,088
Debt issuance costs paid and other financing activities		(16,543	)		(8,465	)		(27,167	)		(31,317	)

Net cash provided by (used for) financing activities		626,587			(634,501	)
Net cash provided by financing activities								2,096,358			231,274

Increase (decrease) in cash and cash equivalents for period		143,536			(17,105	)
Increase in cash and cash equivalents for period								89,848			895,093
Effect of exchange rate changes		9,588			3,125			15,136			4,283
Cash and cash equivalents at beginning of period		83,240			195,541			83,240			195,541

Cash and cash equivalents at end of period	$	236,364		$	181,561		$	188,224		$	1,094,917

Interest paid	$	63,371		$	57,118		$	131,708		$	120,374
Supplemental schedule of non-cash investing activities:
(Decrease) increase in development project construction costs incurred, not paid							$	(9,036	)	$	17,458
Supplemental schedule ofnon-cash financing activities:
Distributions declared, unpaid	$	87,519		$	55,272
Distributions declared, not paid							$	87,519		$	58,333

Medical Properties Trust, Inc., a Maryland corporation, was formed on August 27, 2003, under the Maryland General Corporation Law for the purpose of engaging in the business of investing in, owning, and leasing commercial real estate. Our operating partnership subsidiary, MPT Operating Partnership, L.P., (the “Operating Partnership”) through which we conduct all of our operations, was formed in September 2003. Through another wholly-owned subsidiary, Medical Properties Trust, LLC, we are the sole general partner of the Operating Partnership. At present, we directly own substantially all of the limited partnership interests in the Operating Partnership and have elected to report our required disclosures and that of the Operating Partnership on a combined basis except where material differences exist.

We have operated as a real estate investment trust (“REIT”) since April 6, 2004, and accordingly, elected REIT status upon the filing in September 2005 of the calendar year 2004 federal income tax return. Accordingly, we will generally not be subject to federal income tax in the United States (“U.S.”), provided that we continue to qualify as a REIT and our distributions to our stockholders equal or exceed our taxable income. Certain activities we undertake must be conducted by entities which we elected to be treated as taxable REIT subsidiaries (“TRSs”). Our TRSs are subject to both U.S. federal and state income taxes. For our properties located outside the U.S., we are subject to local taxes; however, we do not expect to incur additional taxes in the U.S. as such income will flow through our REIT.

Our primary business strategy is to acquire and develop real estate and improvements, primarily for long-term lease to providers of healthcare services such as operators of general acute care hospitals, inpatient physical rehabilitation hospitals, long-term acute care hospitals, surgery centers, centers for treatment of specific conditions such as cardiac, pulmonary, cancer, and neurological hospitals, and other healthcare-oriented facilities. We also make mortgage and other loans to operators of similar facilities. In addition, we may obtain profits or equity interests in our tenants, from time to time, in order to enhance our overall return. We manage our business as a single business segment. All of our properties are located in the U.S. and Europe.

Unaudited Interim Condensed Consolidated Financial Statements: The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information, including rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles (“GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and ~~six~~nine month periods ended ~~June~~September 30, 2017, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017. The condensed consolidated balance sheet at December 31, 2016 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.

For information about significant accounting policies, refer to the consolidated financial statements and footnotes thereto included in our Annual Report on Form10-K for the year ended December 31, 2016. During the ~~six~~nine months ended ~~June~~September 30, 2017, there were no material changes to these policies.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers.” Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service. ~~Entities may use a full~~This standard is effective for us beginning January 1, 2018, and we plan to adopt under the modified retrospective approach or report the cumulative effect as of the date of adoption. On April 1, 2015, the FASB proposed deferring the effective date of this standard by one year to December 15, 2017, for annual reporting periods beginning after that date. The FASB also proposed permitting early adoption of the standard, but not before the original effective date of December 15, 2016.approach. We ~~are still evaluating this standard but~~ do not expect this standard to have a significant impact on our financial results upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements and interest income from loans, which are specifically excluded from ASU No. 2014-09.

~~In February 2016,~~ Under ASU No. 2014-09, we do expect more transactions to qualify as sales of real estate with gains on sales being recognized earlier than under current accounting guidance, as the FASB issued ASU 2016-02, “Leases”, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new ~~standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases~~guidance is based on ~~the principle~~transfer of control versus whether or not the ~~lease is effectively~~seller has continuing involvement. Thus, we expect to record an approximate $2 million adjustment to retained earnings upon adoption of ASU No. 2014-09 to fully recognize a ~~financed purchase by the lessee. This classification will determine whether lease expense is recognized based~~gain on ~~an effective interest method or on a straight line basis over the term of the lease. A lessee is also~~real estate sold in prior years that was required to ~~record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will~~ be ~~accounted for similar to~~deferred under existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. The ASU is not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this standard and the impact to us from both a lessor and lessee perspective.accounting guidance.

In January 2017, the FASB issued ASUNo. 2017-01, “Clarifying the Definition of a Business” (“ASU2017-01”). The amendments in ASU2017-01 provide an initial screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, in which case, the transaction would be accounted for as an asset acquisition rather than as a business combination. In addition, ASU2017-01 clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. A reporting entity must apply the amendments in ASU2017-01 using a prospective approach. We ~~expect to~~will adopt ASU2017-01 on January 1, 2018 for our 2018 fiscal year. Upon adoption, we expect to recognize a majority of our real estate acquisitions as asset transactions rather than business combinations, which will result in the capitalization of third party transaction costs that are directly related to an acquisition. Indirect and internal transaction costs will continue to be expensed, but we do not expect to include these costs as an adjustment in deriving normalized funds from operations in the future. We expect this change in accounting, once adopted, may decrease our normalized funds from operations by $1 million to $2 million per quarter.

~~Certain amounts~~In February 2016, the FASB issued ASU 2016-02, “Leases”, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases.

We expect to adopt this new standard on January 1, 2019. We are continuing to evaluate this standard and the impact to us from both a lessor and lessee perspective. However, we do have leases in which we are the ~~consolidated financial statements for prior periods have been reclassified~~lessee, including ground leases, on which certain of our facilities reside, along with corporate office and equipment leases, that will be required to ~~conform~~be recorded on our balance sheet upon adoption of this standard. From a lessor perspective, we do expect certain non-lease components (including property taxes, insurance and other operating expenses that the tenants of our facilities are required to pay pursuant to our “triple-net” leases) to be recorded gross versus net of the ~~current period presentation.~~respective expenses upon adoption of this standard in 2019 in accordance with ASU No. 2014-09.

At ~~June~~September 30, 2017, we had loans to and/or equity investments in certain variable interest entities (“VIEs”), which are also tenants of our facilities. We have determined that we are not the primary beneficiary of these

VIEs. The carrying value and classification of the related assets and maximum exposure to loss as a result of our involvement with these VIEs at ~~June~~September 30, 2017 are presented below (in thousands):


VIE Type	Maximum Loss Exposure(1)		Asset Type Classification	Carrying Amount(2)		Maximum Loss Exposure(1)		Asset Type Classification	Carrying Amount(2)
Loans, net	$	328,111	Mortgage and other loans	$	236,174	$	331,857	Mortgage and other loans	$	235,287
Equity investments	$	12,922	Other assets	$	—	$	13,242	Other assets	$	—

For the VIE types above, we do not consolidate the VIE because we do not have the ability to control the activities (such as theday-to-day healthcare operations of our borrower or investees) that most significantly impact the VIE’s economic performance. As of ~~June~~September 30, 2017, we were not required to provide any material financial support through a liquidity arrangement or otherwise to our unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash short falls).

Typically, our loans are collateralized by assets of the borrower (some assets of which are on the premises of facilities owned by us) and further supported by limited guarantees made by certain principals of the borrower.

See Note 3 and 7 for additional description of the nature, purpose and activities of our more significant VIEs and interests therein, such as Ernest Health, Inc. (“Ernest”).


	Six Months Ended June 30,					Nine Months Ended September 30,
	2017			2016		2017			2016
Assets Acquired
Land and land improvements	$	86,434		$	6,382	$	196,094		$	13,602
Building		420,731			36,455		987,442			125,744
Intangible lease assets — subject to amortization (weighted average useful life 28.4 years for 2017 and 25.8 years for 2016)		54,044			4,154
Intangible lease assets — subject to amortization (weighted average useful life 28.7 years for 2017 and 19.4 years for 2016)							128,961			10,754
Net investments in direct financing leases		40,450			63,000		40,450			63,000
Mortgage loans							700,000			—
Equity investments							100,000			—
Liabilities assumed		(878	)		—		(878	)		—

Total assets acquired	$	600,781		$	109,991	$	2,152,069		$	213,100
Loans repaid (1)							—			(93,262	)

Total net assets acquired						$	2,152,069		$	119,838

The purchase price allocations attributable to the 2017 acquisitions and certain acquisitions made in the ~~second half~~last quarter of 2016 are preliminary. When all relevant information is obtained, resulting changes, if any, to our provisional purchase price allocation will be ~~retrospectively~~ adjusted to reflect new information obtained about the facts and circumstances that existed as of the respective acquisition dates that, if known, would have affected the measurement of the amounts recognized as of those dates.

On ~~June 22,~~September 29, 2017, we acquired anfrom IASIS Healthcare LLC (“IASIS”) a portfolio of ten acute care ~~hospital~~hospitals and one behavioral health facility, along with ancillary land and buildings, that are located in Arizona, Utah, Texas, and Arkansas. The portfolio is now operated by Steward Health Care System LLC (“Steward”), which separately completed its acquisition of IASIS on September 29, 2017. Our investment in the portfolio includes the acquisition of eight acute care hospitals and one behavioral health facility for approximately $700 million, the making of $700 million in mortgage loans on two acute care hospitals, and a $100 million minority equity contribution in Steward, for a combined investment of approximately $1.5 billion. The nine facilities acquired are being leased to Steward pursuant to the original long-term master lease agreement entered into in October 2016 that had an initial 15-year term with three 5-year extension options, plus annual inflation-based escalators. The terms of the mortgage loan are substantially similar to the master lease.

On May 1, 2017, we acquired eight hospitals previously affiliated with Community Health Systems, Inc. in Florida, Ohio, and Pennsylvania for an aggregate purchase price of $301.3 million. These facilities are leased to Steward, pursuant to the original long-term master lease with Steward.

During the third quarter of 2017, we acquired two rehabilitation hospitals in Germany for aan aggregate purchase price of ~~€19.4~~€39.2 million, ~~(€18.6~~in addition to 11 rehabilitation hospitals in Germany that we acquired in the second quarter of ~~which has been funded to date). This property is~~2017 for an aggregate purchase price of €127 million. These 13 properties are leased to affiliates of Median Kliniken S.a.r.l. (“MEDIAN”), ~~one of our current tenants, pursuant to an existing27-year~~ ~~master lease agreement that ends in December 2042 with terms similar to the master lease agreement reached with MEDIAN in 2015.~~

~~During the second quarter of 2017, we acquired 11 rehabilitation hospitals in Germany for an aggregate purchase price of €127 million. These 11 properties are leased to affiliates of MEDIAN,~~ pursuant to a third master lease that has ~~terms similar to the original master lease in 2015 with~~ a fixed term ending in August ~~2043.~~2043 with annual escalators at the greater of one percent or 70% of German consumer price index. These acquisitions are ~~part~~the final properties of the portfolio of 20 properties in Germany that we agreed to acquire in July 2016 for €215.7 million, of which seven properties totaling €49.5 million closed in December 2016. ~~See Note 10~~

On June 22, 2017, we acquired an acute care hospital in Germany for a purchase price of €19.4 million of which €18.6 million was paid upon closing with the remainder being paid over four years. This property is leased to affiliates of MEDIAN, pursuant to an ~~update on~~existing master lease agreement that ends in December 2042 with annual escalators at the ~~final two properties totaling €39.2 million that closed after June 30, 2017.~~greater of one percent or 70% of the German consumer price index.

On January 30, 2017, we acquired an inpatient rehabilitation hospital in Germany for €8.4 million. This acquisition was the final property to close as part of the six hospital portfolio that we agreed to buy in September 2016 for an aggregate amount of €44.1 million. This property is leased to affiliates of MEDIAN pursuant to the original long-term master lease agreement reached with MEDIAN in 2015.

On June 1, 2017, we acquired the real estate assets of Ohio Valley Medical Center, a218-bed acute care hospital located in Wheeling, West Virginia, and the East Ohio Regional Hospital, a139-bed acute care hospital in Martins Ferry, Ohio, from Ohio Valley Health Services, anot-for-profit entity in West Virginia, for an aggregate purchase price of approximately $40 million. We simultaneously leased the facilities to Alecto Healthcare Services LLC (“Alecto”), the current operator of three facilities in our portfolio, pursuant to a lease with a15-year initial term with 2% annual minimum rent increases and three5-year extension options. The facilities are cross-defaulted and cross-collateralized with our other hospitals currently operated by Alecto. We also agreed to provide up to $20.0 million in capital improvement funding on these two facilities - none of which has been funded to date. With these acquisitions, we also obtained a 20% interest in the operator of these facilities.

On May 1, 2017, we acquired eight hospitals previously affiliated with Community Health Systems, Inc. in Florida, Ohio, and Pennsylvania for an aggregate purchase price of $301.3 million. These facilities are leased to Steward Health Care System LLC (“Steward”), pursuant to the existing long-term master lease entered into with Steward in October 2016.

~~On May 1, 2017, we acquired~~ the real estate of St. Joseph Regional Medical Center, a145-bed acute care hospital in Lewiston, Idaho for $87.5 million. This facility is leased to RCCH, ~~Healthcare Partners (“RCCH”),~~ pursuant to the existing long-term master lease entered into with RCCH in April 2016.

From the respective acquisition dates, the properties acquired in 2017 contributed ~~$8.2~~$16.7 million of revenue and ~~$6.0~~$12.7 million of income (excluding related acquisition expenses and taxes) for the three months ended ~~June~~September 30, 2017, and ~~$8.4~~$25.1 million of revenue and ~~$6.1~~$18.8 million of income (excluding related acquisition expenses and taxes) for the ~~six~~nine months ended ~~June~~September 30, 2017. In addition, we expensed ~~$9.1~~$5.4 million and ~~$9.6~~$15.6 million of acquisition-related costs on these 2017 acquisitions for the three and ~~six~~nine months ended ~~June~~September 30, 2017, respectively.

On July 22, 2016, we acquired an acute care facility in Olympia, Washington in exchange for a $93.3 million loan and an additional $7 million in cash. The property has been leased to RCCH on terms substantially similar to those of the existing long-term master lease entered into with RCCH in April 2016.

On June 22, 2016, we closed on the last property of the €688 million MEDIAN transaction, that was announced on April 29, 2015, for a purchase price of €41.6 million. Upon acquisition, this property became subject to an existing master lease between us and affiliates of MEDIAN that has a lease term ending December 2042 and annual escalators at the greater of one percent or 70% of the German consumer price index.

On May 2, 2016, we acquired an acute care hospital in Newark, New Jersey for an aggregate purchase price of $63 million leased to Prime Healthcare Services, Inc. (“Prime”) pursuant to a new fifth master lease, which had a15-year term with three five-year extension options, plus consumer price-indexed increases, limited to a 2%

floor. Furthermore, we committed to advance an additional $30 million to Prime over a three-year period to be used solely for capital additions to the real estate; any such additions will be added to the basis upon which the lessee will pay us rents.

~~On June 22, 2016, we closed on the last property~~ None of the ~~original €688~~additional $30 million ~~MEDIAN transaction for a purchase price of €41.6 million. Upon acquisition, this property became subject~~has been funded to an existing master lease between us and affiliates of MEDIAN. The master lease had an initial start date of July 1, 2015, an initial term of 27 years, and provided for an initial GAAP lease rate of 9.3%, with annual escalators at the greater of one percent or 70% of the German consumer price index.date.

From the respective acquisition dates, the properties acquired induring the nine months ended September 30, 2016, contributed ~~$1.1~~$4.6 million and $3.8 million of revenue and income (excluding related acquisition ~~expenses and taxes)~~expenses), respectively, for the three ~~and six~~ months ended ~~June~~September 30, 2016. From the respective acquisition dates, the properties acquired during the nine months ended September 30, 2016 contributed $5.7 million and $4.9 million of revenue and income (excluding related acquisition expenses), respectively, for the nine months ended September 30, 2016. In addition, we incurred $2.4 million of acquisition-related costs on the 2016 acquisitions for ~~both~~the nine months ended September 30, 2016.

The following unaudited supplemental pro forma operating data is presented for the three and ~~six~~nine months ended ~~June~~September 30, ~~2016.~~2017 and 2016, as if each acquisition was completed on January 1, 2016 and January 1, 2015 for the period ended September 30, 2017 and 2016, respectively. Supplemental pro forma earnings were adjusted to exclude acquisition-related costs on consummated deals incurred. The unaudited supplemental pro forma operating data is not necessarily indicative of what the actual results of operations would have been assuming the transactions had been completed as set forth above, nor do they purport to represent our results of operations for future periods (in thousands, except per share/unit amounts).

During the first ~~six~~nine months of 2017, we completed construction on the following facilities:

In April 2017, we completed the acquisition of the long leasehold interest of a development site in Birmingham, England from the Circle Health Group (“Circle”) (the tenant of our existing site in Bath, England) for a purchase price of £2.7 million. Simultaneously with the acquisition, we entered into contracts with the property landlord and the Circle committing us to construct an acute care hospital on the site. Our total development costs are anticipated to be approximately £30 million. Circle is contracted to enter into a lease of the hospital following completion of construction for an initial15-year term with rent to be calculated based on our total development costs.

See table below for a status update on our current development projects (in thousands):

On March 31, 2017, we sold the EASTAR Health System real estate located in Muskogee, Oklahoma, which was leased to RCCH. Total proceeds from this transaction were approximately $64 million resulting in a gain of $7.4 million, partially offset by a $0.6 millionnon-cash charge to revenue towrite-off related straight-line rent receivables on this property.

Effective April 30, 2016, our investment in the operator of Capella Healthcare, Inc. (“Capella”) merged with Regional Care Hospital Partners, Inc. (“Regional Care”) (an affiliate of certain funds managed by affiliates of Apollo Global Management, LLC. (“Apollo”)) to form RCCH. As part of the transaction, we received net proceeds of approximately $550 million including approximately $492 million for our equity investment and loans made as part of the original Capella transaction that closed on August 31, 2015. In addition, we received $210 million in prepayment of two mortgage loans for hospitals in Russellville, Arkansas, and Lawton, Oklahoma, that we made in connection with the original Capella transaction. We made a new $93.3 million loan for a hospital property in Olympia, Washington that was subsequently converted to real estate on July 22, 2016. Additionally, we and an Apollo affiliate invested $50 million each in unsecured senior notes issued by RegionalCare, which we sold to a large institution on June 20, 2016 at par. The proceeds from this transaction represented the recoverability of our investment in full, except for transaction costs incurred of $6.3 million.

We maintained our ownership of five hospitals in Hot Springs, Arkansas; Camden, South Carolina; Hartsville, South Carolina; Muskogee, Oklahoma; and McMinnville, Oregon. Pursuant to the transaction described above, the underlying leases, one of which is a master lease covering all but one property, was amended to shorten the initial fixed lease term, increase the security deposit, and

eliminate the lessees’ purchase option provisions. Due to this lease amendment, we reclassified the lease of the properties under the master lease from a direct finance lease (“DFL”) to an operating lease. This reclassification resulted in awrite-off of $2.6 million in unbilled DFL rent in the 2016 second quarter.

On May 23, 2016, we sold five properties (three of which were in Texas and two in Louisiana) that were leased and operated by Post Acute Medical (“Post Acute”). As part of this transaction, our outstanding loans of $4 million were paid in full, and we recovered our investment in the operations. Total proceeds from this transaction were $71 million resulting in a net gain of approximately $15 million.

On June 17, 2016, we sold the Atrium Medical Center real estate located in Corinth, Texas, which was leased and operated by Corinth Investor Holdings. Total proceeds from the transaction were $28 million resulting in a gain on real estate of approximately $8 million. This gain on real estate was offset by approximately $9 million ofnon-cash charges that included thewrite-off of our investment in the operations of the facility, straight-line rent receivables, and a lease intangible.

On July 20, 2016, we sold three inpatient rehabilitation hospitals located in Texas and operated by HealthSouth Corporation (“HealthSouth”) for $111.5 million, resulting in a net gain of approximately $45 million.

The sales in 2017 and 2016 were not strategic shifts in our operations, and therefore the results of operations related to these facilities were not reclassified as discontinued operations.

The following represents the operating results (excluding gain on sale, transaction costs, and impairment or other non-cash charges) from the properties which sold during ~~the first half of~~ 2016 (excluding loans repaid in the Capella Transaction) for the periods presented (in thousands):


	For the Three Months					For the Six Months
	Ended June 30,					Ended June 30,					For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2017		2016			2017		2016			2017		2016		2017		2016
Revenues	$	—	$	1,139		$	—	$	3,700		$	—	$	244	$	—	$	7,851
Real estate depreciation and amortization		—		(357	)		—		(857	)		—		—		—		(1,754	)
Property-related expenses		—		(67	)		—		(106	)		—		—		—		(114	)
Other income (expense)		—		(9	)		—		(68	)		—		45		—		(23	)

Income from real estate dispositions, net	$	—	$	706		$	—	$	2,669		$	—	$	289	$	—	$	5,960

At ~~June~~September 30, 2017, leases on two Alecto facilities, 15 Ernest facilities and 10 Prime facilities are accounted for as DFLs. The components of our net investment in DFLs consisted of the following (in thousands):


	As of June 30, 2017			As of December 31, 2016			As of September 30, 2017			As of December 31, 2016
Minimum lease payments receivable	$	2,329,161		$	2,207,625		$	2,312,621		$	2,207,625
Estimated residual values		448,098			407,647			448,098			407,647
Less: Unearned income		(2,084,016	)		(1,967,170	)		(2,064,890	)		(1,967,170	)

Net investment in direct financing leases	$	693,243		$	648,102		$	695,829		$	648,102

On April 4, 2017, we announced that we had agreed in principle with Deerfield Management Company, L.P. (“Deerfield”), a healthcare-only investment firm, to the restructuring in bankruptcy of Adeptus Health, a current tenant and operator of facilities representing less than 5% of our total gross assets. In furtherance of the restructuring, Adeptus Health and certain of its subsidiaries filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code on April 19, 2017. Funds advised by Deerfield acquired Adeptus Health’s outstanding bank debt and Deerfield ~~has~~ agreed to provide additional financing, along with operational and managerial support, to Adeptus Health as part of the restructuring.

The Adeptus Health restructuring and terms of our agreement with Deerfield ~~provide~~provided for the payment to us of 100% of the rent payable during the restructuring and the assumption by Deerfield of ~~approximately 80% of the facilities under~~all our master ~~lease agreement~~leases and related agreements with Adeptus Health at current rental rates. Through ~~August 4,~~November 3, 2017, Adeptus Health is current on its rent obligations to us.

On September 29, 2017, the United States Bankruptcy Court for the Northern District of Texas, Dallas Division, entered an order confirming the Debtors’ Third Amended Joint Plan of Reorganization under Chapter 11 of the Bankruptcy Code (the “Plan”). The Plan became effective on October 2, 2017 (the “Confirmation Effective Date”). In connection with the confirmation of the Plan, Deerfield agreed that it would assume all of the master leases and related agreements between us and Adeptus Health, cure all defaults that had arisen prior to the commencement of the bankruptcy proceedings with respect to all properties, and continue to pay rent with respect to all but 16 of the 56 Adeptus Health properties according to the terms of the master leases and related agreements. Rent will remain the same, and a previously disclosed rent concession was removed from the terms. We ~~have agreed~~plan to re-lease or sell the remaining 16 properties, and Adeptus Health will continue to pay rent with respect to those 16 properties until the earlier of (a) transition to a ~~post bankruptcy $3.1 million concession~~new operator is complete, (b) two years following the Confirmation Effective Date (for one facility), (c) one year following the Confirmation Effective Date (for seven facilities), (d) six months following the Confirmation Effective Date (for three facilities), and (e) three months following the Confirmation Effective Date (for five facilities). These lease or sale transactions are expected to be completed by the end of 2019. Although no assurances can be made that we will ~~reduce our rental revenue by approximately $220 thousand annually over~~not recognize a loss in the ~~remaining14-year~~ ~~initial lease term.~~future, we believe the sale or re-leasing of the assets related to these 16 facilities will not result in any material loss or impairment.

On April 4, 2017, we ~~also~~ announced that our Louisiana freestanding emergency facilities then-operated by Adeptus Health (with a total budgeted investment of approximately $24.5 million) had beenre-leased to Ochsner Clinic Foundation (“Ochsner”), a health care system in the New Orleans area. ~~The leases provide~~We incurred a non-cash charge of $0.5 million to write-off the straight-line rent receivables associated with the previous Adeptus Health lease on these properties. On October 18, 2017, Ochsner agreed to an amended and restated lease that provided for initial terms of 15 years with a 9.2% average minimum lease rate based on our total development and construction ~~cost. Under these leases, Ochsner also has~~cost, as well as the ~~right to purchase the freestanding emergency facilities (i) at our cost within two years~~addition of ~~rent commencement or (ii) for the greater of fair market value or our cost after suchtwo-year~~ ~~period. We incurred anon-cash~~ ~~charge of $0.5 million towrite-off~~ ~~the straight-line rent receivables associated with the previous Adeptus Health lease on these properties.~~

~~In addition, we expect tore-lease~~ or sell 13 Texas facilities that are not being assumed as part of the Adeptus Health restructuring representing approximately 15% of the current Adeptus Health master-leased portfolio. These lease or sale transactions are expected to be completed by the end of 2018, and Adeptus Health is obligated to pay contractual rent to us under the master lease until the earlier of (a) transition to a new operator is complete, or (b) one year following Adeptus Health’s emergence from bankruptcy (for seven of the Texas facilities) or 90 days following Adeptus Health’s emergence from bankruptcy (for the remainder of the Texas facilities).three five-year renewal options.

In the first half of 2017, a subsidiary of the operator of our Hoboken facility acquired 20% of our subsidiary that owns the real estate for $10 million, which ~~increases~~increased its interest in our real estate entity to 30%. This transaction is reflected in the non-controlling interest line of our condensed consolidated balance sheets.


	As of June 30, 2017		As of December 31, 2016		As of September 30, 2017		As of December 31, 2016
Mortgage loans	$	1,062,558	$	1,060,400	$	1,777,555	$	1,060,400
Acquisition loans		120,048		121,464		119,256		121,464
Working capital and other loans		32,920		34,257		32,453		34,257

	$	1,215,526	$	1,216,121	$	1,929,264	$	1,216,121

As of September 30, 2017, our mortgage loans consist of loans made to four operators that are secured by the real estate of 14 properties, and include the $700 million investment made on September 29, 2017, as part of the Steward Transaction. Ournon-mortgage loans typically consist of loans to our tenants for acquisitions and working capital purposes. At ~~June~~September 30, 2017, acquisition loans includes ~~$114.6~~$114.4 million in loans to Ernest.

Our revenue concentration for the ~~six~~nine months ended ~~June~~September 30, 2017 as compared to the prior year is as follows (dollars in thousands):


	For the Six Months Ended June 30, 2017					For the Six Months Ended June 30, 2016					For the Nine Months Ended September 30, 2017					For the Nine Months Ended September 30, 2016
Operators	Total Revenue		Percentage of Total Revenue			Total Revenue		Percentage of Total Revenue			Total Revenue		Percentage of Total Revenue			Total Revenue		Percentage of Total Revenue
Steward (1)											$	114,776		23.0	%	$	20,969		5.4	%
Prime	$	63,059		19.5	%	$	58,859		22.5	%		94,644		18.9	%		89,389		23.1	%
Steward		58,278		18.0	%		—		—
MEDIAN		47,744		14.8	%		47,745		18.3	%		73,793		14.8	%		70,242		18.1	%
Ernest		35,269		10.9	%		33,322		12.8	%		53,007		10.6	%		50,564		13.0	%
Adeptus Health		26,137		8.1	%		16,205		6.2	%		39,638		7.9	%		25,873		6.7	%
RCCH		19,632		6.1	%		32,909		12.6	%		30,668		6.1	%		42,776		11.0	%
Other operators		73,085		22.6	%		72,259		27.6	%		93,258		18.7	%		88,041		22.7	%

Total	$	323,204		100.0	%	$	261,299		100.0	%	$	499,784		100.0	%	$	387,854		100.0	%


	For the Six Months Ended June 30, 2017					For the Six Months Ended June 30, 2016					For the Nine Months Ended September 30, 2017					For the Nine Months Ended September 30, 2016
U.S. States and Other Countries	Total Revenue		Percentage of Total Revenue			Total Revenue		Percentage of Total Revenue			Total Revenue		Percentage of Total Revenue			Total Revenue		Percentage of Total Revenue
Massachusetts	$	53,159		16.5	%	$	—		—		$	79,741		16.0	%	$	—		—
Texas		49,851		15.4	%		48,256		18.5	%		74,489		14.9	%		72,811		18.8	%
California		33,123		10.3	%		33,187		12.7	%		49,681		9.9	%		49,724		12.8	%
New Jersey		21,852		6.8	%		18,243		7.0	%		32,756		6.6	%		28,398		7.3	%
Arizona		15,542		4.8	%		11,722		4.5	%		23,902		4.8	%		17,678		4.6	%
All other states		93,080		28.7	%		99,931		38.2	%		147,606		29.5	%		143,289		36.9	%

Total U.S.	$	266,607		82.5	%	$	211,339		80.9	%	$	408,175		81.7	%	$	311,900		80.4	%
Germany	$	54,576		16.9	%	$	47,745		18.3	%	$	88,525		17.7	%	$	72,718		18.8	%
United Kingdom, Italy, and Spain		2,021		0.6	%		2,215		0.8	%		3,084		0.6	%		3,236		0.8	%

Total International	$	56,597		17.5	%	$	49,960		19.1	%	$	91,609		18.3	%	$	75,954		19.6	%

Grand Total	$	323,204		100.0	%	$	261,299		100.0	%	$	499,784		100.0	%	$	387,854		100.0	%

On a total gross asset basis, which is total assets before accumulated depreciation/amortization, assumes all real estate binding commitments on new investments and unfunded amounts on development deals and commenced capital improvement projects are fully funded (see Notes 9 and 10 of Item 1 on this Form10-Q), and assumes cash on hand is fully used in these transactions, our concentration as of ~~June~~September 30, 2017 as compared to December 31, 2016 is as follows (dollars in thousands):


	As of June 30, 2017					As of December 31, 2016					As of September 30, 2017					As of December 31, 2016
Operators	Total Gross Assets		Percentage of Total Gross Assets			Total Gross Assets		Percentage of Total Gross Assets			Total Gross Assets		Percentage of Total Gross Assets			Total Gross Assets		Percentage of Total Gross Assets
Steward⁽¹⁾	$	3,410,874		37.4	%	$	1,250,000		17.5	%	$	3,445,379		36.8	%	$	1,609,583		22.5	%
MEDIAN												1,209,767		12.9	%		993,677		13.9	%
Prime		1,116,694		12.2	%		1,144,055		16.0	%		1,118,070		12.0	%		1,144,055		16.0	%
MEDIAN		1,086,109		11.9	%		993,677		13.9	%
Ernest		630,811		6.9	%		627,906		8.8	%		631,501		6.7	%		627,906		8.8	%
RCCH		506,265		5.5	%		566,600		7.9	%		506,265		5.4	%		566,600		7.9	%
Other operators		1,977,356		21.7	%		2,259,980		31.7	%		1,992,448		21.3	%		1,900,397		26.7	%
Other assets		401,669		4.4	%		300,903		4.2	%		452,505		4.9	%		300,903		4.2	%

Total	$	9,129,778		100.0	%	$	7,143,121		100.0	%	$	9,355,935		100.0	%	$	7,143,121		100.0	%


	As of June 30, 2017					As of December 31, 2016					As of September 30, 2017					As of December 31, 2016
U.S. States and Other Countries	Total Gross Assets		Percentage of Total Gross Assets			Total Gross Assets		Percentage of Total Gross Assets			Total Gross Assets		Percentage of Total Gross Assets			Total Gross Assets		Percentage of Total Gross Assets
Massachusetts	$	1,262,041		13.8	%	$	1,250,000		17.5	%	$	1,284,156		13.7	%	$	1,250,000		17.5	%
Texas		1,230,945		13.5	%		947,443		13.3	%		1,275,784		13.6	%		947,443		13.3	%
Utah		1,083,152		11.9	%		107,151		1.5	%		1,035,793		11.1	%		107,151		1.5	%
California		542,883		5.9	%		542,889		7.6	%		542,879		5.8	%		542,889		7.6	%
Arizona		486,547		5.3	%		331,834		4.6	%		498,844		5.3	%		331,834		4.6	%
All other states		2,502,791		27.4	%		2,234,332		31.3	%		2,506,538		26.8	%		2,234,332		31.3	%
Other domestic assets		352,748		3.9	%		264,215		3.7	%		397,850		4.3	%		264,215		3.7	%

Total U.S.	$	7,461,107		81.7	%	$	5,677,864		79.5	%	$	7,541,844		80.6	%	$	5,677,864		79.5	%
Germany	$	1,421,350		15.6	%	$	1,281,649		17.9	%	$	1,556,392		16.6	%	$	1,281,649		17.9	%
United Kingdom, Italy, and Spain		198,400		2.2	%		146,920		2.1	%		203,044		2.2	%		146,920		2.1	%
Other international assets		48,921		0.5	%		36,688		0.5	%		54,655		0.6	%		36,688		0.5	%

Total International	$	1,668,671		18.3	%	$	1,465,257		20.5	%	$	1,814,091		19.4	%	$	1,465,257		20.5	%

Grand Total	$	9,129,778		100.0	%	$	7,143,121		100.0	%	$	9,355,935		100.0	%	$	7,143,121		100.0	%

On an individual property basis, we had no investment of any single property greater than ~~3.9%~~3.8% of our total gross assets as of ~~June~~September 30, 2017.


	As of June 30, 2017			As of December 31, 2016			As of September 30, 2017			As of December 31, 2016
Revolving credit facility(A)	$	250,210		$	290,000		$	445,359		$	290,000
Term loans		212,943			263,101			200,000			263,101
6.375% Senior Unsecured Notes due 2022:
Principal amount		350,000			350,000			350,000			350,000
Unamortized premium		1,636			1,814			1,549			1,814

		351,636			351,814			351,549			351,814
5.750% Senior Unsecured Notes due 2020^(A)(B)		—			210,340			—			210,340
4.000% Senior Unsecured Notes due 2022^(A)(B)		571,300			525,850			590,700			525,850
5.500% Senior Unsecured Notes due 2024		300,000			300,000			300,000			300,000
6.375% Senior Unsecured Notes due 2024		500,000			500,000			500,000			500,000
3.325% Senior Unsecured Notes due 2025^(A)(B)		571,300			—			590,700			—
5.250% Senior Unsecured Notes due 2026		500,000			500,000			500,000			500,000
5.000% Senior Unsecured Notes due 2027								1,400,000			—

	$	3,257,389		$	2,941,105		$	4,878,308		$	2,941,105
Debt issue costs, net		(36,335	)		(31,764	)		(46,044	)		(31,764	)

	$	3,221,054		$	2,909,341		$	4,832,264		$	2,909,341

As of ~~June~~September 30, 2017, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):


2017	$	162	$	350,000	(A)
2018		12,781		—
2019		—		—
2020		—		—
2021		250,210		445,359
Thereafter		2,992,600		4,081,400

Total	$	3,255,753	$	4,876,759

On February 1, 2017, we replaced our unsecured credit facility with a new revolving credit and term loan agreement (“Credit Facility”). The new agreement includes a $1.3 billion unsecured revolving loan facility, a $200 million unsecured term loan facility, and a €200 million unsecured term loan facility. The new unsecured revolving loan facility matures in February 2021 and can be extended for an additional 12 months at our option. The $200 million unsecured term loan facility matures on February 1, 2022, and

the €200 million unsecured term loan facility had a maturity date of January 31, 2020; however, it was paid off on March 30, 2017 – see below. The commitment fee on the revolving loan facility is paid at a rate of 0.25%. The term loan and/or revolving loan commitments may be increased in an aggregate amount not to exceed $500 million.

At our election, loans under the Credit Facility may be made as either ABR Loans or Eurodollar Loans. The applicable margin for term loans that are ABR Loans is adjustable on a sliding scale from 0.00% to 0.95% based on our current credit rating. The applicable margin for term loans that are Eurodollar Loans is adjustable on a sliding scale from 0.90% to 1.95% based on our current credit rating. The applicable margin for revolving loans that are ABR Loans is adjustable on a sliding scale from 0.00% to 0.65% based on our current credit rating. The

applicable margin for revolving loans that are Eurodollar Loans is adjustable on a sliding scale from 0.875% to 1.65% based on our current credit rating. The commitment fee is adjustable on a sliding scale from 0.125% to 0.30% based on our current credit rating and is payable on the revolving loan facility. At ~~June~~September 30, 2017, the interest rate in effect on our term loan and revolver was ~~2.72%~~2.74% and ~~2.46%~~2.48%, respectively.

On March 30, 2017, we prepaid and extinguished the €200 million of outstanding term loans under the euro term loan facility portion of our Credit Facility. To fund such prepayment, including accrued and unpaid interest thereon, we used part of the proceeds of the 3.325% Senior Unsecured Notes due 2025 – see discussion below.

On March 4, 2017, we redeemed the €200 million aggregate principal amount of our 5.750% Senior Unsecured Notes due 2020 and incurred a redemption premium of approximately $9 million. We funded this redemption, including the premium and accrued interest, with the proceeds of the new euro term loan (see discussion above) together with cash on hand.

On March 24, 2017, we completed a €500 million senior unsecured notes offering (“3.325% Senior Unsecured Notes due 2025”). Interest on the notes is payable annually on March 24 of each year. The notes pay interest in cash at a rate of 3.325% per year. The notes mature on March 24, 2025. We may redeem some or all of the 3.325% Senior Unsecured Notes due 2025 at any time. If the notes are redeemed prior to 90 days before maturity, the redemption price will be equal to 100% of their principal amount, plus a make-whole premium, plus accrued and unpaid interest up to, but excluding, the applicable redemption date. Within the period beginning on or after 90 days before maturity, the notes may be redeemed, in whole or in part, at a redemption price equal to 100% of their principal amount, plus accrued and unpaid interest to, but excluding, the applicable redemption date. The 3.325% Senior Unsecured Notes due 2025 are fully and unconditionally guaranteed on a senior unsecured basis by us. In the event of a change of control, each holder of the notes may require us to repurchase some or all of our notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest up to, but excluding, the date of the purchase.

On ~~March 30,~~September 7, 2017, we completed a $1.4 billion senior unsecured notes offering (“5.000% Senior Unsecured Notes due 2027”). Interest on the notes is payable annually on April 15 and October 15 of each year, commencing on April 15, 2018. The notes pay interest in cash at a rate of 5.000% per year. The notes mature on October 15, 2027. We may redeem some or all of the notes at any time prior to October 15, 2022 at a “make whole” redemption price. On or after October 15, 2022, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to October 15, 2020, we may redeem up to 40% of the notes at a redemption price equal to 105% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.

We used a portion of the net proceeds from the 5.000% Senior Unsecured Notes due 2027 offering to redeem the $350 million aggregate principal amount of our 6.375% Senior Unsecured Notes due 2022. The notes were repaid on October 7, 2017, and we will incur a debt refinancing charge of approximately $14 million in the fourth quarter of 2017, consisting of an $11.2 million redemption premium along with the write-off of the unamortized premium and deferred debt issuance costs associated with the redeemed notes.

Furthermore, the completion of the 5.000% Senior Unsecured Notes due 2027 offering resulted in the cancellation of the $1.0 billion term loan facility commitment from JP Morgan Chase Bank, N.A. that we received to assist in funding the September 2017 Steward transaction. With this commitment, we paid $5.2 million of underwriting and other fees, which we fully expensed upon the cancellation of the commitment.

On September 29, 2017, we prepaid ~~and extinguished~~ the ~~€200 million~~principal amount of ~~outstanding term loans under~~ the ~~euro term~~mortgage loan ~~facility portion~~on our property in Kansas City, Missouri at par in the amount of ~~our Credit Facility.~~$12.9 million. To fund such prepayment, including accrued and unpaid interest thereon, we used ~~part~~borrowings from the revolving credit facility portion of ~~the proceeds of the 3.325% Senior Unsecured Notes due 2025.~~our Credit Facility.

With the replacement of our old credit facility, the redemption of the 5.750% Senior Unsecured Notes due 2020, ~~and~~ the payoff of our €200 million euro term loan, the cancellation of the $1.0 billion term loan facility commitment, and the payment of our $12.9 million mortgage loan, we incurred a debt refinancing charge of ~~$13.6~~$18.8 million in the first ~~six~~nine months of 2017.

On July 22, 2016, we completed a $500 million senior unsecured notes offering (“5.250% Senior Unsecured Notes due 2026”). Interest on the notes is payable on February 1 and August 1 of each year. Interest on the notes is to be paid in cash at a rate of 5.25% per year. The notes mature on August 1, 2026. We may redeem some or all of the notes at any time prior to August 1, 2021 at a “make whole” redemption price. On or after August 1, 2021, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to August 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 105.25% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.

We used the net proceeds from the 5.250% Senior Unsecured Notes due 2026 offering to redeem our $450 million 6.875% Senior Unsecured Notes due 2021. This redemption resulted in a $22.5 million debt refinancing charge during the 2016 third quarter, consisting of a $15.5 million redemption premium along with the write-off of deferred debt issuance costs associated with the redeemed notes.

On February 22, 2016, we completed a $500 million senior unsecured notes offering (“6.375% Senior Unsecured Notes due 2024”). Interest on the notes is payable on March 1 and September 1 of each year. Interest on the notes is paid in cash at a rate of 6.375% per year. The notes mature on March 1, 2024. We may redeem some or all of the notes at any time prior to March 1, 2019 at a “make whole” redemption price. On or after March 1, 2019, we may redeem some or all of the notes at a premium that will decrease over time. In addition, at any time prior to March 1, 2019, we may redeem up to 35% of the notes at a redemption price equal to 106.375% of the aggregate principal amount thereof, plus accrued and unpaid interest thereon, using proceeds from one or more equity offerings. In the event of a change in control, each holder of the notes may require us to repurchase some or all of the notes at a repurchase price equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest to the date of purchase.

Our debt facilities impose certain restrictions on us, including restrictions on our ability to: incur debts; create or incur liens; provide guarantees in respect of obligations of any other entity; make redemptions and repurchases of our capital stock; prepay, redeem or repurchase debt; engage in mergers or consolidations; enter into affiliated transactions; dispose of real estate or other assets; and change our business. In addition, the credit agreements governing our Credit Facility limit the amount of dividends we can pay as a percentage of normalized adjusted funds from operations (“FFO”), as defined in the agreements, on a rolling four quarter basis. At ~~June~~September 30, 2017, the

dividend restriction was 95% of normalized adjusted FFO. The indentures governing our senior unsecured notes also limit the amount of dividends we can pay based on the sum of 95% of FFO, proceeds of equity issuances and certain other net cash proceeds. Finally, our senior unsecured notes require us to maintain total unencumbered assets (as defined in the related indenture) of not less than 150% of our unsecured indebtedness.

In addition to these restrictions, the Credit Facility contains customary financial and operating covenants, including covenants relating to our total leverage ratio, fixed charge coverage ratio, secured leverage ratio, consolidated adjusted net worth, unsecured leverage ratio, and unsecured interest coverage ratio. This Credit Facility also contains customary events of default, including among others, nonpayment of principal or interest, material inaccuracy of representations and failure to comply with our covenants. If an event of default occurs and is continuing under the Credit Facility, the entire outstanding balance may become immediately due and payable. At ~~June~~September 30, 2017, we were in compliance with all such financial and operating covenants.

On May 1, 2017, we completed an underwritten public offering of approximately 43.1 million shares (including the exercise of the underwriters’30-day option to purchase an additional 5.6 million shares) of our common stock, resulting in net proceeds of approximately $548 million, after deducting offering expenses.

On September 30, 2016, we completed an underwritten public offering of 57.5 million shares (including the exercise of the underwriters’ 30-day option to purchase an additional 7.5 million shares) of our common stock, resulting in net proceeds of $799.5 million, after deducting estimated offering expenses.

During the ~~six~~nine months ended ~~June~~September 30, 2016, we sold approximately 315 million shares of common stock under anat-the-market equity offering program, resulting in net proceeds of approximately ~~$45~~$224 million, after deducting approximately ~~$0.6~~$2.8 million of commissions. There is no availability under this equity offering program at ~~June~~September 30, 2017.

At ~~June~~September 30, 2017, the Company has a 99.89% ownership interest in the Operating Partnership with the remainder owned by three other partners, two of whom are employees and one of whom is the estate of a former director. During the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, the Operating Partnership issued approximately 43.1 million units and approximately 372.5 million units, respectively, in direct response to the common stock offerings by Medical Properties Trust, Inc.

We adopted the 2013 Equity Incentive Plan (the “Equity Incentive Plan”) during the second quarter of 2013, which authorizes the issuance of common stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance units and awards of interests in our Operating Partnership. The Equity Incentive Plan is administered by the Compensation Committee of the Board of Directors. We have reserved 8,196,770 shares of common stock for awards under the Equity Incentive Plan for which 3.3 million shares remain available for future stock awards as of ~~June~~September 30, 2017. Share-based compensation expense totaled ~~$4.4~~$7.1 million and ~~$4.2~~$5.8 million for the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, respectively, of which ~~$0.3~~$0.4 million relates to the acceleration of vestings on time-based awards previously granted to ~~two retiring~~three former board members.

We have various assets and liabilities that are considered financial instruments. We estimate that the carrying value of cash and cash equivalents and accounts payable and accrued expenses approximate their fair values. We estimate the fair value of our interest and rent receivables using Level 2 inputs such as discounting the estimated future cash flows using the current rates at which similar receivables would be made to others with

similar credit ratings and for the same remaining maturities. The fair value of our mortgage loans and working capital loans are estimated by using Level 2 inputs such as discounting the estimated future cash flows using the current rates which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. We determine the fair value of our senior unsecured notes using Level 2 inputs such as quotes from securities dealers and market makers. We estimate the fair value of our revolving credit facility and term loans using Level 2 inputs based on the present value of future payments, discounted at a rate which we consider appropriate for such debt.

Fair value estimates are made at a specific point in time, are subjective in nature, and involve uncertainties and matters of significant judgment. Settlement of such fair value amounts may not be possible and may not be a prudent management decision. The following table summarizes fair value estimates for our financial instruments (in thousands):


													September 30, 2017						December 31, 2016
	June 30, 2017						December 31, 2016						Book			Fair			Book			Fair
Asset (Liability)	Book Value			Fair Value			Book Value			Fair Value			Value			Value			Value			Value
Interest and rent receivables	$	68,537		$	68,698		$	57,698		$	57,707		$	105,817		$	105,803		$	57,698		$	57,707
Loans (1)		984,784			1,009,687			986,987			1,017,428			1,698,866			1,722,912			986,987			1,017,428
Debt, net		(3,221,054	)		(3,384,541	)		(2,909,341	)		(2,966,759	)		(4,832,264	)		(5,032,821	)		(2,909,341	)		(2,966,759	)

Our equity interest in Ernest along with their related loans are measured at fair value on a recurring basis as we elected to account for these investments using the fair value option method. We have elected to account for these investments at fair value due to the size of the investments and because we believe this method is more reflective of current values. We have not made a similar election for other existing equity interests or loans.


							Fair				Asset Type
Asset Type	Fair Value		Cost		Asset Type Classification		Value		Cost		Classification
Mortgage loans	$	115,000	$	115,000		Mortgage loans	$	115,000	$	115,000		Mortgage loans
Acquisition and other loans		115,742		115,742		Other loans		115,398		115,398		Other loans
Equity investments		3,300		3,300		Other assets		3,300		3,300		Other assets

	$	234,042	$	234,042			$	233,698	$	233,698

Our mortgage and other loans with Ernest are recorded at fair value based on Level 2 inputs by discounting the estimated cash flows using the market rates which similar loans would be made to borrowers with similar credit ratings and the same remaining maturities. Our equity investment in Ernest is recorded at fair value based on Level 3 inputs, by using a discounted cash flow model, which requires significant estimates of our investee such as projected revenue and expenses and appropriate consideration of the underlying risk profile of the forecast assumptions associated with the investee. We classify the equity investment as Level 3, as we use certain unobservable inputs to the valuation methodology that are significant to the fair value measurement, and the valuation requires management judgment due to the absence of quoted market prices. For the cash flow model, our observable inputs include use of a capitalization rate, discount rate (which is based on a weighted-average cost of capital), ~~and~~ market interest rates, and our unobservable input includes an adjustment for a marketability discount (“DLOM”) on our equity investment of 40% at ~~June~~September 30, 2017.

In regards to the underlying projection of revenues and expenses used in the discounted cash flow model, such projections are provided by Ernest. However, we will modify such projections (including underlying

assumptions used) as needed based on our review and analysis of Ernest’s historical results, meetings with key members of management, and our understanding of trends and developments within the healthcare industry.

In arriving at the DLOM, we started with a DLOM range based on the results of studies supporting valuation discounts for other transactions or structures without a public market. To select the appropriate DLOM within the range, we then considered many qualitative factors including the percent of control, the nature of the underlying investee’s business along with our rights as an investor pursuant to the operating agreement, the size of investment, expected holding period, number of shareholders, access to capital marketplace, etc. To illustrate the effect of movements in the DLOM, we performed a sensitivity analysis below by using basis point variations (dollars in thousands):


Basis Point Change in Marketability Discount	Estimated Increase (Decrease) In Fair Value			Estimated Increase (Decrease) In Fair Value
+100 basis points	$	(52	)	$	(51	)
- 100 basis points		52			51

Because the fair value of Ernest investments noted above approximate their original cost, we did not recognize any unrealized gains/losses during the first ~~half~~nine months of 2017 or 2016. To date, we have not received any distribution payments from our equity investment in Ernest.


	For the Three Months Ended June 30,						For the Three Months Ended September 30,
	2017			2016			2017			2016
Numerator:
Income from continuing operations	$	73,796		$	53,924
Net income							$	76,881		$	70,543
Non-controlling interests’ share in net income		(381	)		(200	)		(417	)		(185	)
Participating securities’ share in earnings		(100	)		(132	)		(82	)		(154	)

Net income, less participating securities’ share in earnings	$	73,315		$	53,592		$	76,382		$	70,204

Denominator:
Basic weighted-average common shares		349,856			238,082			364,315			246,230
Dilutive potential common shares		463			926			731			1,238

Dilutive weighted-average common shares		350,319			239,008			365,046			247,468


							For the Nine Months Ended September 30,
							2017			2016
Numerator:
Income from continuing operations							$	218,862		$	182,693
Non-controlling interests’ share in continuing operations								(1,013	)		(683	)
Participating securities’ share in earnings								(307	)		(430	)

Income from continuing operations, less participating securities’share in earnings								217,542			181,580
Loss from discontinued operations attributable to MPT common stockholders								—			(1	)

Net income, less participating securities’ share in earnings							$	217,542		$	181,579

Denominator:
Basic weighted-average common shares								345,076			240,607
Dilutive potential common shares								520			825

Dilutive weighted-average common shares								345,596			241,432

   For the Six Months
Ended June 30,
   2017    2016
Numerator:

Income from continuing operations
   $ 141,981    $ 112,150
Non-controlling interests’ share in continuing operations
   (596 )    (498 )
Participating securities’ share in earnings
   (225 )    (276 )




Income from continuing operations, less participating securities’ share in earnings
   141,160    111,376
Loss from discontinued operations attributable to MPT common stockholders
   —      (1 )




Net income, less participating securities’ share in earnings
   $ 141,160    $ 111,375




Denominator:

Basic weighted-average common shares
   335,456    237,796
Dilutive potential common shares
   415    617




Dilutive weighted-average common
shares
   335,871    238,413

Our earnings per common unit were calculated based on the following (in thousands):


	For the Three Months Ended June 30,						For the Three Months Ended September 30,
	2017			2016			2017			2016
Numerator:
Income from continuing operations	$	73,796		$	53,924
Net income							$	76,881		$	70,543
Non-controlling interests’ share in net income		(381	)		(200	)		(417	)		(185	)
Participating securities’ share in earnings		(100	)		(132	)		(82	)		(154	)

Net income, less participating securities’ share in earnings	$	73,315		$	53,592		$	76,382		$	70,204

Denominator:
Basic weighted-average units		349,856			238,082			364,315			246,230
Dilutive potential units		463			926			731			1,238

Dilutive weighted-average units		350,319			239,008			365,046			247,468


	For the Six Months Ended June 30,						For the Nine Months Ended September 30,
	2017			2016			2017			2016
Numerator:
Income from continuing operations	$	141,981		$	112,150		$	218,862		$	182,693
Non-controlling interests’ share in continuing operations		(596	)		(498	)		(1,013	)		(683	)
Participating securities’ share in earnings		(225	)		(276	)		(307	)		(430	)

Income from continuing operations, less participating securities’ share in earnings		141,160			111,376			217,542			181,580
Loss from discontinued operations attributable to MPT Operating Partnership partners		—			(1	)		—			(1	)

Net income, less participating securities’ share in earnings	$	141,160		$	111,375		$	217,542		$	181,579

Denominator:
Basic weighted-average units		335,456			237,796			345,076			240,607
Dilutive potential units		415			617			520			825

Dilutive weighted-average units		335,871			238,413			345,596			241,432

On September 28, 2016, we entered into a definitive agreement to acquire one acute care hospital in Washington for a purchase price of approximately $17.5 million. Upon closing, this facility will be leased to RCCH, pursuant to the current long-term master lease. Closing of the transaction, which is expected to be completed no later than the ~~fourth~~first quarter of ~~2017,~~2018, is subject to customary real estate, regulatory and other closing conditions.

On May 18, 2017, we entered into definitive agreements to invest in a portfolio of ten acute care hospitals and one behavioral health facility currently operated by IASIS Healthcare (“IASIS”) for a combined purchase price and investment of approximately $1.4 billion. Following closing, the portfolio will be operated by Steward, which separately announced a simultaneous merger transaction with IASIS, the completion of which is a condition to our investment.

Pursuant to the terms of an asset purchase agreement with IASIS and its affiliates, dated May 18, 2017, subsidiaries of the Operating Partnership will acquire from IASIS and its affiliates all of their interests in the real estate of eight acute care hospitals and one behavioral health facility for an aggregate purchase price of $700 million. At closing, these facilities will be leased to Steward pursuant to the existing master lease agreement. In addition, pursuant to the terms of the agreement, subsidiaries of the Operating Partnership will make mortgage loans in an aggregate amount of $700 million, secured by first mortgages in two other acute care hospitals. The real estate master lease and mortgage loans will have substantially similar terms, which have an initial fixed term expiration of October 31, 2031 and include three~~5-year~~ ~~extension options, plus annual inflation protected escalators.~~

In addition, in conjunction with the real estate and mortgage loans transactions described above, a subsidiary of the Operating Partnership will also invest approximately $100 million in minority preferred interests of Steward. We will have no management authority or control of Steward except for certain protective rights consistent with a minority passive ownership interest, such as a limited right to approve certain extraordinary transactions.

To assist in funding the Steward commitment, if needed, we received a commitment for a new $1.0 billion term loan facility pursuant to a commitment letter with JP Morgan Chase Bank, N.A. The term loan facility, if funded, would have a maturity date of one year after the date on which it is consummated, and could be extended an additional 12 months at our option. With this commitment, we paid $4.5 million of underwriting and other fees, which will be expensed over the commitment period. Through June 30, 2017, we have expensed approximately $0.8 million as an unutilized financing fee.

We are a party to various legal proceedings incidental to our business. In the opinion of management, after consultation with legal counsel, the ultimate liability, if any, with respect to those proceedings is not presently expected to materially affect our financial position, results of operations or cash flows.

~~As described in Note 3 under the heading “2017 Activity,” on July 20, 2016,~~On October 5, 2017, we entered into definitive agreements to acquire 20three rehabilitation hospitals in Germany for an aggregate purchase price to us of approximately ~~€215.7 million to~~€80 million. Upon closing, the facilities will be leased to ~~affiliates of MEDIAN. As of June 30, 2017, we had closed~~MEDIAN, pursuant to a newlong-term master lease. The lease will begin on 18the day the first property is funded, and the term will be 27 years from the funding date of the ~~20 facilities~~third property. The lease provides for increases of the greater of 1% or 70% of the change in German CPI. Closing of the ~~amount~~transaction, which is expected to begin during the fourth quarter of ~~€176.5 million. The remaining two facilities totaling €39.2 million closed in July 2017.~~2017, is subject to customary real estate, regulatory and other closing conditions.

~~Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.~~

The following discussion and analysis of the consolidated financial condition and consolidated results of operations are presented on a combined basis for Medical Properties Trust, Inc. and MPT Operating Partnership, L.P. as there are no material differences between these two entities.

The following discussion and analysis of the consolidated financial condition and consolidated results of operations should be read together with the condensed consolidated financial statements and notes thereto contained in this Form10-Q and the consolidated financial statements and notes thereto contained in our Annual Report on Form10-K for the year ended December 31, 2016.

This report on Form10-Q contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results or future performance, achievements or transactions or events to be materially different from those expressed or implied by such forward-looking statements, including, but not limited to, the risks described in our Annual Report on Form10-K and as updated in our quarterly reports on Form10-Q for future periods, and current reports on Form8-K as we file them with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934. Such factors include, among others, the following:

Our revenue is derived from rents we earn pursuant to the lease agreements with our tenants, from interest income from loans to our tenants and other facility owners and from profits or equity interests in certain of our tenants’ operations. Our tenants operate in the healthcare industry, generally providing medical, surgical and rehabilitative care to patients. The capacity of our tenants to pay our rents and interest is dependent upon their ability to conduct their operations at profitable levels. We believe that the business environment of the industry segments in which our tenants operate is generally positive for efficient operators. However, our tenants’ operations are subject to economic, regulatory and market conditions that may affect their profitability, which could impact our results. Accordingly, we monitor certain key factors, changes to which we believe may provide early indications of conditions that may affect the level of risk in our portfolio.

Key factors that we consider in underwriting prospective tenants and borrowers and in monitoring the performance of existing tenants and borrowers include the following:

Certain business factors, in addition to those described above that directly affect our tenants and borrowers, will likely materially influence our future results of operations. These factors include:

Refer to our 2016 Annual Report on Form10-K, for a discussion of our critical accounting policies, which include revenue recognition, investment in real estate, purchase price allocation, loans, losses from rent

receivables, stock-based compensation, our fair value option election, and our accounting policy on consolidation. During the ~~six~~nine months ended ~~June~~September 30, 2017, there were no material changes to these policies.

We are a self-advised real estate investment trust (“REIT”) focused on investing in and owningnet-leased healthcare facilities across the U.S. and selectively in foreign jurisdictions. We have operated as a REIT since April 6, 2004, and accordingly, elected REIT status upon the filing of our calendar year 2004 federal income tax return. Medical Properties Trust, Inc. was incorporated under

Maryland law on August 27, 2003, and MPT Operating Partnership, L.P. was formed under Delaware law on September 10, 2003. We conduct substantially all of our business through MPT Operating Partnership, L.P. We acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear most of the costs associated with the property. We also make mortgage loans to healthcare operators collateralized by their real estate assets. In addition, we selectively make loans to certain of our operators through our ~~taxable REIT subsidiaries,~~TRSs, the proceeds of which are typically used for acquisitions and working capital. Finally, from time to time, we acquire a profits or other equity interest in our tenants that gives us a right to share in such tenant’s profits and losses.

At ~~June~~September 30, 2017, our portfolio consisted of ~~256~~271 properties leased or loaned to 3230 operators, of which two are under development and 1214 are in the form of mortgage loans.

Our investments in healthcare real estate, including mortgage and other loans, as well as any equity investments in our tenants are considered a single reportable segment. All of our investments are currently located in the U.S. and Europe. Our total assets are made up of the following (dollars in thousands):


	As of June 30, 2017		% of Total			As of December 31, 2016		% of Total			As of September 30, 2017		% of Total			As of December 31, 2016		% of Total
Real estate owned (gross)	$	5,650,933		77.1	%	$	4,912,320		76.6	%	$	6,463,107		72.4	%	$	4,912,320		76.6	%
Mortgage loans		1,062,558		14.5	%		1,060,400		16.5	%		1,777,555		19.9	%		1,060,400		16.5	%
Other loans		152,968		2.1	%		155,721		2.4	%		151,709		1.7	%		155,721		2.4	%
Construction in progress		18,439		0.3	%		53,648		0.8	%		28,008		0.3	%		53,648		0.8	%
Other assets		442,939		6.0	%		236,447		3.7	%		506,661		5.7	%		236,447		3.7	%

Total assets (1)	$	7,327,837		100.0	%	$	6,418,536		100.0	%	$	8,927,040		100.0	%	$	6,418,536		100.0	%


	For the Three Months Ended June 30, 2017		% of Total			For the Three Months Ended June 30, 2016		% of Total			For the Three Months Ended September 30, 2017		% of Total			For the Three Months Ended September 30, 2016		% of Total
General Acute Care Hospitals (1)	$	114,942		68.9	%	$	76,468		60.5	%	$	119,572		67.7	%	$	78,622		62.1	%
Rehabilitation Hospitals		41,065		24.6	%		38,265		30.3	%		46,485		26.3	%		37,075		29.3	%
Long-term Acute Care Hospitals		10,800		6.5	%		11,567		9.2	%		10,523		6.0	%		10,858		8.6	%

Total revenue	$	166,807		100.0	%	$	126,300		100.0	%	$	176,580		100.0	%	$	126,555		100.0	%


	For the Six Months Ended June 30, 2017		% of Total			For the Six Months Ended June 30, 2016		% of Total			For the Nine Months Ended September 30, 2017		% of Total			For the Nine Months Ended September 30, 2016		% of Total
General Acute Care Hospitals (1)	$	222,068		68.7	%	$	159,978		61.2	%	$	341,640		68.4	%	$	238,600		61.5	%
Rehabilitation Hospitals		79,344		24.6	%		76,388		29.3	%		125,829		25.2	%		113,463		29.3	%
Long-term Acute Care Hospitals		21,792		6.7	%		24,933		9.5	%		32,315		6.4	%		35,791		9.2	%

Total revenue	$	323,204		100.0	%	$	261,299		100.0	%	$	499,784		100.0	%	$	387,854		100.0	%

We have 5762 employees as of ~~August 4,~~November 3, 2017. We believe that any foreseeable increase in the number of our employees will have only immaterial effects on our operations and general and administrative expenses. We believe that our relations with our employees are good. None of our employees are members of any labor union.

Three Months Ended ~~June~~September 30, 2017 Compared to ~~June~~September 30, 2016

Net income for the three months ended ~~June~~September 30, 2017, was ~~$73.4~~$76.5 million, compared to ~~$53.7~~$70.4 million for the three months ended ~~June~~September 30, 2016. This increase is due to additional revenue from the Steward and MEDIAN investments made in the fourth quarter of 2016 and during the ~~second quarter~~first nine months of 2017, partially offset by increased depreciation and acquisition expense and ~~the $16.6~~$44.6 million ~~gain~~of gains on ~~sale of properties~~real estate and other asset dispositions in the 2016 ~~second~~third quarter. Funds from operations (“FFO”), after adjusting for certain items (as more fully described in Reconciliation ofNon-GAAP Financial Measures), was ~~$113.6~~$120.6 million, or ~~$0.32~~$0.33 per diluted share for the 2017 ~~second~~third quarter as compared to ~~$75.5~~$75.1 million, or ~~$0.32~~$0.30 per diluted share for the 2016 ~~second~~third quarter. This ~~50%~~61% increase in FFO per share is primarily due to the increase in revenue from our new investments made since ~~June 2016.~~September 2016, partially offset by more shares outstanding in 2017 from the May 2017 equity offering.

A comparison of revenues for the three month periods ended ~~June~~September 30, 2017 and 2016 is as follows (dollar amounts in thousands):


	2017		% of Total			2016		% of Total			Year over Year Change
Rent billed	$	110,930		62.8	%	$	82,387		65.1	%		34.6	%
Straight-line rent		17,505		9.9	%		9,741		7.7	%		79.7	%
Income from direct financing leases		19,115		10.8	%		14,678		11.6	%		30.2	%
Interest and fee income		29,030		16.5	%		19,749		15.6	%		47.0	%

Total revenues	$	176,580		100.0	%	$	126,555		100.0	%		39.5	%

Our total revenue for the 2017 ~~second~~third quarter is up ~~$40.5~~$50.0 million or ~~32.1%~~39.5% over the prior year. This increase is made up of the following:

Real estate depreciation and amortization during the ~~second~~third quarter of 2017 increased to ~~$29.5~~$31.9 million from ~~$22.8~~$23.9 million in 2016, due to the incremental depreciation from the properties acquired since ~~June~~September 30, 2016 and the development properties completed in 2016 and 2017. In

Property expenses for the 2017 third quarter increased $1.6 million from the prior year quarter as the 2016 ~~second~~third quarter ~~we accelerated~~included $0.9 million reimbursement for property expenses incurred in multiple previous periods from the ~~amortization~~tenant of ~~the lease intangible asset related to~~ our ~~Corinth facility resulting in $1.1 million of additional expense.~~Twelve Oaks facility.

Acquisition expenses increased from ~~$4.8~~$2.7 million in 2016 to ~~$10.8~~$7.4 million in 2017 primarily as a result of the Steward and MEDIAN acquisitions in 2017, including approximately ~~$9.0~~$2.3 million of real estate transfer taxes.

During the three months ended June 30, 2016, we had various dispositions resulting in a net gain on sale of real estate and other asset dispositions of $16.6 million and impairment charges of $7.4 million (see Note 3 to Item 1 of this~~Form 10-Q~~ ~~for further details).~~

General and administrative expenses totaled ~~$15.1~~$15.0 million for the 2017 ~~second~~third quarter, which is ~~9.0%~~8.5% of total revenues, down from ~~9.5%~~9.7% of total revenues in prior year ~~second~~third quarter. The drop in general and administrative expenses as a percentage of revenue is primarily due to our business model as we can generally increase our revenue significantly without increasing our head count and related expenses at the same rate. On a dollar basis, general and administrative expenses were up ~~$3.0~~$2.7 million from the prior year ~~second~~third quarter due primarily to the growth of our company, including increases in travel, international administration, costs associated with opening a European office, and compensation related to increased ~~headcount and public company board expenses.~~headcount.

Interest expense, for the quarters ended ~~June~~September 30, 2017 and 2016, totaled ~~$39.7~~$42.8 million and ~~$41.5~~$40.3 million, respectively. This ~~decrease~~increase is primarily related to the higher average debt balance for the 2017 quarter compared to the prior year to fund our acquisition activity. The impact on interest expense from the higher debt balance was partially offset by lower interest rates ~~on fixed rate debt held during the quarter ended June 30, 2017 as compared to June 30, 2016.~~year-over-year. Our ~~weighted average~~weighted-average interest rate was 4.6% for the quarter ended ~~June~~September 30, 2017, ~~which is a slight decrease from 5.1%~~compared to 5.2% in 2016. ~~We did incur approximately $0.8~~

With the redemption of the $450 million in ~~unutilized facility fees~~senior unsecured notes during the quarter ended September 30, 2016, we incurred $22.5 million in debt refinancing charges ($15.5 million of which was a redemption premium). During the 2017 ~~second~~third quarter, we incurred $4.4 million of charges primarily related to structuring and underwriting fees associated with the ~~short term~~termination of theshort-term loan commitment we made in anticipation of the ~~$1.5 billion~~ Steward ~~acquisition described~~acquisition.

During the three months ended September 30, 2016, we sold three HealthSouth properties resulting in a net gain on sale of approximately $45 million (see Note ~~9 and in~~3 to Item 1 of this Form~~10-Q.~~ ~~See Note 4 to our Condensed Consolidated Financial Statements in Item 1 to this Form~~10-Q for further ~~information on our debt activities.~~details).

Earnings from our equity interests was ~~$2.8~~$3.4 million for the 2017 ~~second~~third quarter, up ~~$1.6~~$2.1 million from the prior year primarily related to our increased ownership in and the improved operating results of the operator of our Hoboken ~~facility.~~facility, along with our first quarter to generate income on our IMED investment.

Income tax expense typically includes U.S. federal and state income taxes on our TRS entities, as well asnon-U.S. income based or withholding taxes on certain investments located in jurisdictions outside the U.S. ~~The income~~Income tax ~~benefit~~expense of $0.5 million for the three months ended ~~June~~September 30, 2017, was primarily due to ~~$1.3~~$1.1 million of foreign tax expense related to our German investments offset partially by $0.6 million of tax benefit recognized on approximately ~~$8.8~~$2 million of acquisition costs incurred on our European investments.

We utilize the asset and liability method of accounting for income taxes. Deferred tax assets are recorded to the extent we believe these assets will more likely than not be realized. In making such determination, all available positive and negative evidence is considered, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and recent financial performance. Based upon our review of all positive and negative evidence, including our three-year cumulativepre-tax book loss position in many entities, we concluded that a full valuation allowance should continue to be recorded against the majority of our U.S and certain of our international net deferred tax assets at ~~June~~September 30, 2017. In the future, if we determine that it is more likely than not that we will realize our U.S. and foreign net deferred tax assets, we will reverse the applicable portion of the valuation allowance, recognize an income tax benefit in the period in which such determination is made, and incur higher income taxes in future periods.

~~Six~~Nine Months Ended ~~June~~September 30, 2017 Compared to ~~June~~September 30, 2016

Net income for the ~~six~~nine months ended ~~June~~September 30, 2017, was ~~$141.4~~$217.8 million compared to net income of ~~$111.7~~$182.0 million for the ~~six~~nine months ended ~~June~~September 30, 2016, primarily due to additional revenue from the MEDIAN, Steward, and RCCH investments made in the fourth quarter of 2016 and the ~~second quarter~~first nine months of 2017, incremental revenue from completed development projects ~~a $7.4 million gain on the sale of our facility in Muskogee, Oklahoma,~~ and

increased income from our equity investments, partially offset by ~~a $14.4 million debt refinancing charge in 2017,~~ higher depreciation ~~expenses~~expense from investments made subsequent to ~~June~~September 30, 2016, increased acquisition and travel expense due to more foreign investments, and ~~the $16.7~~approximately $54 million ~~gain~~in higher gains on sale of ~~several~~ properties in the first ~~half~~nine months of 2016. FFO, after adjusting for certain items (as more fully described in Reconciliation ofNon-GAAP Financial Measures), was ~~$219.6~~$340.1 million, or ~~$0.65~~$0.98 per diluted share for the first ~~six~~nine months in 2017 as compared to ~~$159.0~~$234.1 million, or ~~$0.67~~$0.97 per diluted share for the first ~~six~~nine months of 2016. This ~~38.1%~~45.3% increase in FFO is primarily due to the increase in revenue from acquisitions and completed development projects made since ~~June~~September 2016, while FFO per share is ~~lower~~only slightly higher in the first ~~half~~nine months of 2017 compared to prior year due to more shares outstanding from the September 2016 and May 2017 equity offerings.

A comparison of revenues for the ~~six~~nine month periods ended ~~June~~September 30, 2017 and 2016 is as follows (dollar amounts in thousands):


	2017		% of Total			2016		% of Total			Year over Year Change			2017		% of Total			2016		% of Total			Year over Year Change
Rent billed	$	200,210		61.9	%	$	152,021		58.2	%		31.7	%	$	311,140		62.3	%	$	234,408		60.4	%		32.7	%
Straight-line rent		29,056		9.0	%		16,768		6.4	%		73.3	%		46,561		9.3	%		26,509		6.8	%		75.6	%
Income from direct financing leases		36,192		11.2	%		32,503		12.4	%		11.3	%		55,307		11.1	%		47,181		12.2	%		17.2	%
Interest and fee income		57,746		17.9	%		60,007		23.0	%		(3.8	%)		86,776		17.3	%		79,756		20.6	%		8.8	%

Total revenues	$	323,204		100.0	%	$	261,299		100.0	%		23.7	%	$	499,784		100.0	%	$	387,854		100.0	%		28.9	%

Our total revenue for the first ~~six~~nine months of 2017 is up ~~$61.9~~$111.9 million or ~~23.7%~~28.9% over the prior year. This increase is made up of the following:

incremental revenue from acquisitions made after June 30, 2016, $11.2 million is incremental revenue from development properties that were completed and put into service in 2016 and 2017, $1.1 million is incremental revenue from capital additions made to existing facilities in 2017 and 2016, $5.6 million relates to the conversion of certain RCCH facilities in 2016 from direct financing leases into operating leases, and a $0.5 million straight-line rent~~write-off~~ related to our Corinth facility in the 2016 second quarter. These increases are partially offset by $7.2 million lower revenue related to dispositions and $2.2 million in foreign currency fluctuations.

Real estate depreciation and amortization during the first ~~six~~nine months of 2017 increased to ~~$57.1~~$89.0 million from ~~$44.0~~$67.9 million in the same period of 2016, primarily due to the incremental depreciation from the properties acquired and the development properties completed in 2016 and 2017. In the 2016 second quarter, we accelerated the amortization of the lease intangible asset related to our Corinth facility resulting in $1.1 million of additional expense.

Property expenses for the first nine months of 2017 increased $2.4 million compared to 2016. This increase is primarily due to the reimbursement to us in the 2016 third quarter of $0.8 million by the tenant of our Twelve Oaks facility for property expenses incurred in previous periods.

Acquisition expenses increased from ~~$3.7~~$6.4 million in 2016 to ~~$13.6~~$21.0 million in 2017 primarily as a result of the MEDIAN and Steward acquisitions in 2017, including ~~$9.5~~$11.7 million of real estate transfer taxes incurred on the MEDIAN acquisitions.

During the six months ended June 30, 2017, we sold the Muskogee, Oklahoma facility resulting in a net gain on sale of real estate of $7.4 million, while in the first six months of 2016, we had various dispositions resulting in a net gain on sale of real estate and other asset dispositions of $16.7 million and impairment charges of $7.4 million (see Note 3 to Item 1 of this Form~~10-Q~~ ~~for further details).~~

Earnings from our equity interests increased from a loss of $3.8 million in 2016 to a gain of $4.5 million in 2017. The loss in 2016 includes $5.3 million of acquisition expenses, representing our share of such expenses incurred by our Italian joint venture to acquire its eight hospital properties. In addition, 2017 includes $3.0 million of additional income related to our increased ownership in and improved operating results of the operator of our Hoboken facility.

General and administrative expenses in the first ~~six~~nine months of 2017 totaled ~~$28.3~~$43.3 million, which is 8.7% of revenues down from ~~9.0%~~9.2% of revenues in the prior year. The decline in general and administrative expenses as a percentage of revenues is primarily due to our business model as we can generally increase our revenues significantly without increasing our head count and related expense at the same rate. On a dollar basis, general and administrative expenses were up ~~$4.8~~$7.5 million from the prior year first ~~six~~nine months due primarily to increases in travel, international administration, costs associated with opening a European office, compensation related to increased headcount and public company board expenses.

During the nine months ended September 30, 2017, we sold the Muskogee, Oklahoma facility resulting in a net gain on sale of real estate of $7.4 million, while in the first nine months of 2016, we had various dispositions resulting in a net gain on sale of real estate and other asset dispositions of $61.3 million and impairment charges of $7.3 million (see Note 3 to Item 1 of this Form 10-Q for further details).

Earnings from our equity interests increased from a loss of $2.6 million in 2016 to a gain of $7.9 million in 2017. The loss in 2016 includes $5.3 million of acquisition expenses, representing our share of such expenses incurred by our Italian joint venture to acquire its eight hospital properties. In addition, 2017 includes $4.7 million of additional income related to our increased ownership in and improved operating results of the operator of our Hoboken facility, along with additional income from our IMED investment in the 2017 third quarter.

Interest expense remained relatively flat year-over-year as we incurred $120.5 million for the first ~~six~~nine months of 2017 ~~and 2016 totaled $77.7~~compared to $121.1 million ~~and $80.9 million, respectively. This decrease is primarily related to lower interest rates on our fixed rate debt. Our weighted average interest rate is~~

~~slightly lower period over period – 4.6%~~ for the first ~~six~~nine months of 2016. Our average debt balance for 2017 has been higher than 2016 due to continued growth of the company; however, its impact on interest expense has been more than offset by lower interest rates. Our weighted-average interest rate for the first nine months of 2017 ~~and 4.7%~~was 4.6% versus 4.9% in the same period for 2016.

With the redemption of the $450 million in senior unsecured notes, we incurred $22.5 million in debt refinancing charges ($15.5 million of which was a redemption premium) during the first ~~six~~nine months of 2016. ~~We did incur $14.4~~During the first nine months of 2017, we incurred $18.8 million of ~~unutilized facility fees/~~debt refinancing ~~costs in~~charges related to the ~~first half~~replacement of ~~2017 from the new~~our credit facility, ~~and~~the payoff of our ~~5.750% Senior Unsecured Notes due 2020 (see Note 4 in Item 1 to thisForm 10-Q~~ ~~for further information on~~€200 million euro loan, the prepayment of our ~~debt activities) along~~$12.9 million term loan, and structuring and underwriting fees associated with the termination of the short-term loan commitment we made in anticipation of the Steward acquisition ~~described in~~(see Note ~~9 in~~4 to Item 1 of this Form~~10-Q.~~ 10-Q for further details).

Income tax expense for the ~~six~~nine months ended ~~June~~September 30, 2017 decreased by ~~$0.4 million~~$390 thousand from the same period in 2016 primarily due to ~~$1.4~~$1.7 million of benefit recognized on approximately ~~$9.6~~$10.7 million of acquisition costs incurred on our European investments in ~~the first half of~~ 2017. This tax benefit recognized in 2017 was offset by additional tax expense from ~~the acquisition of additional international properties and a distribution from one of~~ our international ~~equity~~ investments, which were not realized in ~~2017.~~2016 due to a valuation allowance position. These valuation allowances were released in the 2016 fourth quarter.

Investors and analysts following the real estate industry utilize funds from operations, or FFO, as a supplemental performance measure. FFO, reflecting the assumption that real estate asset values rise or fall with market conditions, principally adjusts for the effects of GAAP depreciation and amortization of real estate assets, which assumes that the value of real estate diminishes predictably over time. We compute FFO in accordance with the definition provided by the National Association of Real Estate Investment Trusts, or NAREIT, which represents net income (loss) (computed in accordance with GAAP), excluding gains (losses) on sales of real estate and impairment charges on real estate assets, plus real estate depreciation and amortization and after adjustments for unconsolidated partnerships and joint ventures.

In addition to presenting FFO in accordance with the NAREIT definition, we also disclose normalized FFO, which adjusts FFO for items that relate to unanticipated ornon-core events or activities or accounting changes that, if not noted, would make comparison to prior period results and market expectations less meaningful to investors and analysts.

We believe that the use of FFO, combined with the required GAAP presentations, improves the understanding of our operating results among investors and the use of normalized FFO makes comparisons of our operating results with prior periods and other companies more meaningful. While FFO and normalized FFO are relevant and widely used supplemental measures of operating and financial performance of REITs, they should not be viewed as a substitute measure of our operating performance since the measures do not reflect either depreciation and amortization costs or the level of capital expenditures and leasing costs necessary to maintain the operating performance of our properties, which can be significant economic costs that could materially impact our results of operations. FFO and normalized FFO should not be considered an alternative to net income (loss) (computed in accordance with GAAP) as indicators of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity.

The following table presents a reconciliation of net income attributable to MPT common stockholders to FFO for the three and ~~six~~nine months ended ~~June~~September 30, 2017 and 2016 (in thousands, except per share data):


	For the Three Months Ended						For the Six Months Ended						For the Three Months Ended						For the Nine Months Ended
	June 30, 2017			June 30, 2016			June 30, 2017			June 30, 2016			September 30, 2017			September 30, 2016			September 30, 2017			September 30, 2016
FFO information:
Net income attributable to MPT common stockholders	$	73,415		$	53,724		$	141,385		$	111,651		$	76,464		$	70,358		$	217,849		$	182,009
Participating securities’ share in earnings		(100	)		(132	)		(225	)		(276	)		(82	)		(154	)		(307	)		(430	)

Net income, less participating securities’ share in earnings	$	73,315		$	53,592		$	141,160		$	111,375		$	76,382		$	70,204		$	217,542		$	181,579
Depreciation and amortization		30,027			23,335			58,126			44,807			32,618			24,374			90,744			69,181
Gain on sale of real estate		—			(22,613	)		(7,413	)		(22,653	)		(18	)		(44,515	)		(7,431	)		(67,168	)

Funds from operations	$	103,342		$	54,314		$	191,873		$	133,529		$	108,982		$	50,063		$	300,855		$	183,592
Write-off of straight line rent and other		—			3,063			1,117			3,063			—			—			1,117			3,063
Transaction costs fromnon-real estate dispositions		—			5,975			—			5,975
Transaction costs from non-real estate dispositions .														—			(101	)		—			5,874
Acquisition expenses, net of tax benefit		9,539			4,801			12,184			9,034			7,166			2,689			19,350			11,723
Impairment charges		—			7,375			—			7,375			—			(80	)		—			7,295
Unutilized financing fees / debt refinancing costs		751			—			14,380			4			4,414			22,535			18,794			22,539

Normalized funds from operations	$	113,632		$	75,528		$	219,554		$	158,980		$	120,562		$	75,106		$	340,116		$	234,086

Per diluted share data:
Net income, less participating securities’ share in earnings	$	0.21		$	0.22		$	0.42		$	0.47		$	0.21		$	0.28		$	0.63		$	0.75
Depreciation and amortization		0.08			0.10			0.17			0.18			0.09			0.10			0.26			0.29
Gain on sale of real estate		—			(0.09	)		(0.02	)		(0.09	)		—			(0.18	)		(0.02	)		(0.28	)

Funds from operations	$	0.29		$	0.23		$	0.57		$	0.56		$	0.30		$	0.20		$	0.87		$	0.76
Write-off of straight line rent and other		—			0.01			—			0.01			—			—			—			0.01
Transaction costs fromnon-real estate dispositions		—			0.03			—			0.03
Transaction costs from non-real estate dispositions .														—			—			—			0.03
Acquisition expenses, net of tax benefit		0.03			0.02			0.04			0.04			0.02			0.01			0.06			0.05
Impairment charges		—			0.03			—			0.03			—			—			—			0.03
Unutilized financing fees / debt refinancing costs		—			—			0.04			—			0.01			0.09			0.05			0.09

Normalized funds from operations	$	0.32		$	0.32		$	0.65		$	0.67		$	0.33		$	0.30		$	0.98		$	0.97

Total gross assets is total assets before accumulated depreciation/amortization and assumes all real estate binding commitments on new investments and unfunded amounts on development deals and commenced capital improvement projects are fully funded, and assumes cash on hand is fully used in these transactions. We believe total gross assets is useful to investors as it provides a more current view of our portfolio and allows for a better understanding of our concentration levels as our binding commitments close and our other commitments are fully funded. The following table presents a reconciliation of total assets to total gross assets (in thousands):


	As of June 30, 2017			As of December 31, 2016			As of September 30, 2017			As of December 31, 2016
Total Assets	$	7,327,837		$	6,418,536		$	8,927,040		$	6,418,536
Add:
Binding real estate commitments on new investments⁽¹⁾		1,562,290			288,647			112,012			288,647
Unfunded amounts on development deals and commenced capital improvement projects⁽²⁾		91,189			194,053			86,227			194,053
Accumulated depreciation and amortization		384,826			325,125			418,880			325,125
Less:
Cash and cash equivalents		(236,364	)		(83,240	)		(188,224	)		(83,240	)

Total Gross Assets	$	9,129,778		$	7,143,121		$	9,355,935		$	7,143,121

During the ~~first half of~~nine months ended September 30, 2017, we generated ~~$154.9~~$219.9 million of cash flows from operating activities, primarily consisting of rent and interest from mortgage and other loans. We used these operating cash flows along with cashon-hand to fund our dividends of ~~$151.7 million and certain investing activities.~~$239.2 million.

Certain ~~other~~ investing and financing activities in ~~the first half of~~ 2017 included:

a) On February 1, 2017, we replaced our credit facility with a new facility resulting in a $50 million reduction in our U.S. dollar term loan and a new €200 million term loan;

b) On March 4, 2017, we redeemed our 5.750% Senior Unsecured Notes due 2020 for €200 million plus a redemption premium using proceeds from our €200 million term loan and cash on hand;

c) On March 24, 2017, we completed a €500 million senior unsecured notes offering and used a portion of the proceeds to pay off our €200 million term loan, and the remaining proceeds were used to acquire 12 facilities ~~to be~~ leased to MEDIAN for €146.4 million;

d) On March 31, 2017, we sold the EASTAR Health System real estate in Muskogee, Oklahoma for approximately $64 million; ~~and~~

e) On May 1, 2017, we completed an underwritten public offering of 43.1 million shares resulting in net proceeds of approximately $548 million. We used a portion of these proceeds to acquire eight facilities for $301.3 million (leased to Steward), a facility in Idaho for $87.5 million (leased to RCCH) and two other facilities for $40 million (leased to Alecto).;

~~In the first half of~~f) On September 7, 2017, we ~~received~~completed a ~~commitment~~senior unsecured notes offering for $1.4 billion and used a ~~new $1.0~~portion of the proceeds to redeem our 6.375% Senior Unsecured Notes due 2022 in October 2017 for $350 million plus a redemption premium, and the remaining proceeds, along with borrowings from our revolving credit facility, were used to acquire 11 facilities and ancillary properties leased to Steward for $1.4 billion ~~term~~and to make a $100 million equity investment in Steward; and

g) On September 29, 2017, we prepaid our Northland mortgage loan ~~facility pursuant to a commitment letter with JP Morgan Chase Bank, N.A. This term loan facility is available to partially fund~~in the ~~$1.5 billion Steward transaction disclosed in Note 9 to Item 1~~amount of ~~this Form10-Q.~~ ~~This term loan has not been funded as of August 4, 2017.~~$12.9 million.

During the ~~first half of~~nine months ended September 30, 2016, we generated ~~$137.3~~$168.3 million of cash flows from operating activities, primarily consisting of rent and interest from mortgage and other loans. We used these operating cash flows along with cashon-hand to fund our dividends of ~~$104.8~~$160.1 million and certain investing activities.

In regards to other financing activities, to, delever and finance the Steward acquisition in October 2016, we did the following:

a) On February 22, 2016, we completed ~~the 6.375% Senior Unsecured Notes due 2024~~a senior unsecured notes offering for $500 million.

b) On April 30, 2016, we closed on the Capella Transaction (as further discussed in Note 3 to Item 1 of thisForm 10-Q) resulting in net proceeds of $550 million along with an additional $50 million once we sold our investment in RegionalCare bonds in June 2016.

c) On May 23, 2016, we sold our investment in five properties leased and operated by Post Acute for $71 million.

d) On June 17, 2016, we sold our investment in one property leased and operated by Corinth Investor Holdings for $28 million. ~~Finally, during June~~

e) On July 13, 2016, we completed a new $500 million senior unsecured notes offering. We used the net proceeds from this offering to redeem our $450 million 6.875% Senior Unsecured Notes due 2021, which was completed on August 12, 2016. Net proceeds from the notes offering after redemption approximated $19 million, and we incurred a one-time charge of $22.5 million related to the redemption (see Note 4 to Item 1 of this Form 10-Q for further details).

f) On July 20, 2016, we sold 3three facilities leased to HealthSouth for $111.5 million, and

g) We sold 82.7 million shares ~~under~~(including 10.3 million sold to Cerberus affiliates on October 7, 2016) through ourat-the-market equity offering program, ~~realizing net~~a public equity offering and a private placement generating proceeds of approximately ~~$45 million. We used these proceeds to reduce our revolving credit facility by $1.1 billion during 2016 and fund our remaining investing activities.~~$1.2 billion.

Short-term Liquidity Requirements:As of ~~June 30,~~November 3, 2017 (and after the redemption of the $350 million 6.375% Senior Unsecured

Notes due 2022 on October 7, 2017), we do not have ~~less than $0.2 million in~~any debt principal payments due until the revolving credit facility comes due in ~~2017~~

2021, which we can extend for an additional 12 months — see debt maturity schedule below. At ~~August 4,~~November 3, 2017, our availability under our revolving credit facility plus cashon-hand approximated ~~$1.2~~$0.7 billion. We believe this liquidity and our current monthly cash receipts from rent and loan interest is sufficient to fund our operations, debt and interest obligations, the expected funding

requirements on our development projects, and dividends in order to comply with REIT requirements for the next twelve months. In addition, with the additional availability from the $1.0 billion term loan facility commitment as discussed above, we believe we have the liquidity to fund the $1.5 billion Steward transaction firm commitment. We do believe other sources of capital (including senior unsecured notes, entering into joint venture arrangements and strategic property sales) are generally available as well. However, there is no assurance that such capital will be available when needed for such firm commitment or that our attempts to gain such capital will be successful.

Long-term Liquidity Requirements: Exclusive of the revolving credit facility (which we can extend for an additional year to February

2022), and after the redemption of the $350 million 6.375% Senior Unsecured Notes due 2022, we do not have ~~only $13 million in~~any debt principal payments due over the next five years (see debt maturity schedule below). With our liquidity at ~~August 4,~~November 3, 2017 of approximately ~~$1.2~~$0.7 billion along with our current monthly cash receipts from rent and loan interest, we believe we have the liquidity available to us to fund our operations, debt and interest obligations, dividends in order to comply with REIT requirements, and the expected funding requirements on our development projects currently.

However, in order to fund our investment strategies, ~~(including the $1.5 billion Steward transaction firm commitment)~~while maintaining a prudent leverage ratio, and to fund debt maturities coming due in 2022 and later years, additional capital will be needed, and we believe the following sources of capital are generally available in the market and we may access one or a combination of them:

However, there is no assurance that conditions will be favorable for such possible transactions or that our plans will be successful.

As of ~~June~~September 30, 2017, principal payments due on our debt (which exclude the effects of any discounts, premiums, or debt issue costs recorded) are as follows (in thousands):


2017	$	162	$	350,000	(A)
2018		12,781		—
2019		—		—
2020		—		—
2021		250,210		445,359
Thereafter		2,992,600		4,081,400

Total	$	3,255,753	$	4,876,759

We presented our contractual obligations in our Annual Report on Form10-K for the fiscal year ended December 31, 2016. ~~Except for~~For the nine months ended September 30, 2017, changes to our debt related contractual obligations included the issuance of our new Credit Facility, ~~and~~ the 3.325% Senior Unsecured Notes due 2025, and the 5.000% Senior Unsecured Notes due 2027, along with redemption of our 5.750% Senior Unsecured Notes due 2020 ~~there have been no significant changes in the debt related obligation during the six months ended June~~and prepayment of our $12.9 million term loan. Subsequent to September 30, ~~2017.~~2017, we redeemed our 6.375% Senior Unsecured Notes due 2022. See Note 4 of Item 1 of this Form10-Q for more detailed information. ~~In regards to purchase obligations, the only significant change in 2017 was our $1.5 billion Steward commitment – see Note 9 of Item 1 of this Form10-Q~~ ~~for further details.~~

The following table updates our contractual obligations schedule for the ~~new Credit Facility,~~debt activity, described above, for the ~~3.325%~~nine months ended September 30, 2017 along with the post September 30, 2017 early redemption of our 6.375% Senior Unsecured Notes due ~~2025 offering, along with the redemption of our 5.750% Senior Unsecured Notes due 2020~~2022 (in thousands):


Contractual Obligations	Less Than 1 Year		1-3 Years		3-5 Years		After 5 Years		Total		Less Than 1 Year		1-3 Years		3-5 Years		After 5 Years		Total
Revolving credit facility (1)	$	9,384	$	18,768	$	255,684	$	—	$	283,836	$	14,287	$	28,574	$	450,122	$	—	$	492,983
Term loans		18,932		11,046		208,780		—		238,758
Term loan												5,556		11,127		207,444		—		224,127
3.325% Senior Unsecured Notes due 2025		18,996		37,991		37,991		628,287		723,265		19,641		39,282		39,282		649,622		747,827
5.750% Senior Unsecured Notes due 2020		—		—		—		—		—		—		—		—		—		—
6.375% Senior Unsecured Notes due 2022												364,381		—		—		—		364,381
5.000% Senior Unsecured Notes due 2027												39,667		140,000		140,000		1,785,000		2,104,667

The table below is a summary of our distributions declared during the two year period ended ~~June~~September 30, 2017:


Declaration Date	Record Date	Date of Distribution	Distribution per Share		Record Date	Date of Distribution	Distribution per Share
August 17, 2017					September 14, 2017	October 12, 2017	$	0.24
May 25, 2017	June 15, 2017	July 14, 2017	$	0.24	June 15, 2017	July 14, 2017	$	0.24
February 16, 2017	March 16, 2017	April 13, 2017	$	0.24	March 16, 2017	April 13, 2017	$	0.24
November 10, 2016	December 8, 2016	January 12, 2017	$	0.23	December 8, 2016	January 12, 2017	$	0.23
August 18, 2016	September 15, 2016	October 13, 2016	$	0.23	September 15, 2016	October 13, 2016	$	0.23
May 19, 2016	June 16, 2016	July 14, 2016	$	0.23	June 16, 2016	July 14, 2016	$	0.23
February 19, 2016	March 17, 2016	April 14, 2016	$	0.22	March 17, 2016	April 14, 2016	$	0.22
November 12, 2015	December 10, 2015	January 14, 2016	$	0.22	December 10, 2015	January 14, 2016	$	0.22
August 20, 2015	September 17, 2015	October 15, 2015	$	0.22

We intend to pay to our stockholders, within the time periods prescribed by the Internal Revenue Code (“Code”), all or substantially all of our annual taxable income, including taxable gains (if any) from the sale of real estate and recognized gains on the sale of securities. It is our policy to make sufficient cash distributions to stockholders in order for us to maintain our status as a REIT under the Code and to avoid corporate income and excise taxes on undistributed income. See Note 4 to our condensed consolidated financial statements in Item 1 to this Form10-Q for any restrictions placed on dividends by our existing credit facility.

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. We seek to mitigate the effects of fluctuations in interest rates by matching the terms of new investments with new long-term fixed rate borrowings to the extent possible. We may or may not elect to use financial derivative instruments to hedge interest rate or foreign currency exposure. For interest rate hedging, these decisions are principally based on our policy to match our variable rate investments with comparable borrowings, but are also based on the general trend in interest rates at the applicable dates and our perception of the future volatility of interest rates. For foreign currency hedging, these decisions are principally based on how our investments are financed, the long-term nature of our investments, the need to repatriate earnings back to the U.S. and the general trend in foreign currency exchange rates.

In addition, the value of our facilities will be subject to fluctuations based on changes in local and regional economic conditions and changes in the ability of our tenants to generate profits, all of which may affect our ability to refinance our debt, if necessary. The changes in the value of our facilities would be impacted also by changes in “cap” rates, which is measured by the current base rent divided by the current market value of a facility.

Our primary exposure to market risks relates to fluctuations in interest rates and foreign currency. The following analyses present the sensitivity of the market value, earnings and cash flows of our significant financial instruments to hypothetical changes in interest rates and exchange rates as if these changes had occurred. The hypothetical changes chosen for these analyses reflect our view of changes that are reasonably possible over aone-year period. These forward looking disclosures are selective in nature and only address the potential impact from these hypothetical changes. They do not include other potential effects which could impact our business as a result of changes in market conditions. In addition, they do not include measures we may take to minimize our exposure such as entering into future interest rate swaps to hedge against interest rate increases on our variable rate debt.

For fixed rate debt, interest rate changes affect the fair market value but do not impact net income to common stockholders or cash flows. Conversely, for floating rate debt, interest rate changes generally do not

affect the fair market value but do impact net income to common stockholders and cash flows, assuming other factors are held constant. At ~~June~~September 30, 2017, our outstanding debt totaled ~~$3.2~~$4.8 billion, which consisted of fixed-rate debt of ~~$2.7~~$4.2 billion and variable rate debt of ~~$0.5~~$0.6 billion. If market interest rates increase by 1%, the fair value of our debt at ~~June~~September 30, 2017 would decrease by ~~$3.8~~$8.0 million. Changes in the fair value of our fixed rate debt will not have any impact on us unless we decided to repurchase the debt in the open market.

If market rates of interest on our variable rate debt increase by 1%, the increase in annual interest expense on our variable rate debt would decrease future earnings and cash flows by ~~$0.1~~$0.2 million per year. If market rates of interest on our variable rate debt decrease by 1%, the decrease in interest expense on our variable rate debt would increase future earnings and cash flows by ~~$0.1~~$0.2 million per year. This assumes that the average amount outstanding under our variable rate debt for a year is ~~$0.5~~$0.6 billion, the balance of such variable rate debt at ~~June~~September 30, 2017.

With our investments in Germany and throughout Europe, we are subject to fluctuations in the euro and British pound to U.S. dollar currency exchange rates. Increases or decreases in the value of the euro to U.S. dollar and the British pound to U.S. dollar exchange rates may impact our financial condition and/or our results of operations. Based solely on operating resultsto-date in 2017 and on an annualized basis, if the euro exchange rate were to change by 5%, our FFO would change by approximately ~~$3.7~~$4.0 million. Based solely on operating resultsto-date in 2017 and on an annualized basis, if the British pound exchange rate were to change by 5%, our FFO would change by less than $0.2 million.

We have adopted and maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required byRule 13a-15(b), under the Securities Exchange Act of 1934, as amended, we have carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information required to be disclosed by us in the reports that we file with the SEC.

There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

The information contained in Note 9 “Contingencies” of Part I, Item 1 of this Quarterly Report on Form10-Q is incorporated by reference into this Item 1.

Except to the extent set forth below or as otherwise disclosed in this Quarterly Report on Form10-Q, there have been no material changes to the Risk Factors as presented in our Annual Report on Form10-K for the year ended December 31, 2016.

~~We may fail to consummate the Steward transactions at all or on the terms described herein, and, if the Steward transactions are completed, we may be subject to additional risks.~~

If the Steward transactions (described in Note 9 of Item 1) are not completed, we could be subject to a number of risks that may adversely affect our business, financial condition, cash flows and the trading price of our common stock, including:

In addition to the risks described in our 2016 10-K relating to healthcare facilities that we may purchase from time to time, if the Steward transactions are completed, we would also be subject to additional risks, including without limitation the following:

Our revenues ~~will be~~are dependent upon our relationship with and success of our largest tenants, Steward, Prime, MEDIAN, Ernest, RCCH and Adeptus Health.

As of ~~June~~September 30, 2017, affiliates of Steward, MEDIAN, Prime, ~~MEDIAN,~~ Ernest, RCCH and Adeptus Health ~~represent 37.4%~~represented 36.8%, ~~12.2%~~12.9%, ~~11.9%~~12.0%, ~~6.9%~~6.7%, ~~5.5%~~5.4% and ~~4.6%~~4.5%, respectively, of our total ~~total~~ gross ~~assets.~~assets (which consist primarily of real estate leases and mortgage loans).

Our relationships with these operators and their financial performance and resulting ability to satisfy their lease and loan obligations to us are material to our financial results and our ability to service our debt and make distributions to our stockholders. We are dependent upon the ability of these operators to make rent and loan payments to us, and any failure to meet these obligations could have a material adverse effect on our financial condition and results of operations.

Our tenants operate in the healthcare industry, which is highly regulated by federal, state, and local laws and changes in regulations may negatively impact our tenants’ operations until they are able to make the appropriate adjustments to their business. For example, recent modifications to regulations concerning patient criteria and reimbursement for long-term acute care hospitals, or LTACHs, have resulted in volume and profitability declines in certain facilities operated by Ernest.

We are aware of various federal and state inquiries, investigations and other proceedings currently affecting several of our tenants and would expect such government compliance and enforcement activities to be ongoing at any given time with respect to one or more of our tenants, either on a confidential or public basis. During the second quarter of 2016, the Department of Justice joined a lawsuit against Prime alleging irregular admission practices intended to increase the number of inpatient care admissions of Medicare patients, including unnecessarily classifying some patients as “inpatient” rather than “observation”. Other large acute hospital operators have also recently defended similar allegations, sometimes resulting in financial settlements and agreements with regulators to modify admission policies, resulting in lower reimbursements for those patients.

Our tenants experience operational challenges fromtime-to-time, and this can be even more of a risk for those tenants that grow via acquisitions in a short time frame like Steward, Prime, Adeptus Health ~~etc.~~ and others.

In May 2017, Prime advised that it would be delayed in furnishing its 2016 financial statements to its lenders and that it would take a significant write-down to its accounts receivables. Prime has received a notice of default from its lenders related to its failure to furnish its 2016 financials on a timely basis. As a result of these developments, S&P has downgraded Prime’s corporate credit rating and senior secured term loan credit rating. These financial and operational setbacks affecting Prime may adversely impact its ability to make required lease and interest payments to us.

The ability of ~~a company~~our tenants and operators to integrate newly acquired businesses into their existing operational, financial reporting and collection systems is ~~important to ensure the success of the overall enterprise.~~critical towards ensuring their continued success. If such integration is not successfully implemented in a timely manner, operators can be negatively impacted whether it be through write-offs of uncollectible accounts receivable (similar to Prime’s expected ~~write-offs of six to seven percent of their 2016 revenues)~~write-offs) or ~~worse~~even insolvency in ~~the case of Adeptus Health.~~certain extreme cases.

On April 19, 2017, Adeptus Health filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Northern District of Texas, Dallas Division, to pursue a Chapter 11 reorganization plan (the “Plan”). Pursuant to and subject to the terms of the Plan, on the effective date of the Plan, among other things, all of Adeptus Health’s existing facility leases with us will be assumed by Deerfield, and, in accordance with section 365(b) of the Bankruptcy Code, all cure amounts due and owing to the MPT lessors under such leases shall be paid.

Any failure of Adeptus Health to achieve a successful restructuring in bankruptcy could affect its ability to pay us rent and therefore have a significant adverse effect on our financial condition and results of operations.

Anfurther adverse result to any of Steward, Prime, MEDIAN, Ernest, ~~Prime,~~RCCH or Adeptus Health ~~or one of our larger tenants~~ in regulatory proceedings or financial or operational setbacks may have a material adverse effect on the relevant tenant’s operations and financial condition and on its ability to make required lease and loan payments to us. If any further one of these tenants files for bankruptcy protection, we may not be able to collect any pre-filing amounts owed to us by such tenant. In addition, in a bankruptcy proceeding, such tenant may terminate our lease(s), in which ~~could negatively affect~~case we would have a general unsecured claim that would likely be for less than the full amount owed to us. Any secured claims we have against such tenant may only be paid to the extent of the value of the collateral, which may not cover any or all of our ~~ability~~losses. If we are ultimately required to ~~service our debt~~find one or more tenant-operators to lease one or more properties currently leased by such tenant, we may face delays and ~~make distributions to our stockholders.~~increased costs in locating a suitable replacement tenant. The protections that we have in place to protect against such failure or delay, which can include letters of credit, cross default provisions, parent guarantees, repair reserves and the right to exercise remedies including the termination of the lease and replacement of the operator, may prove to be insufficient, in whole or in part, or may entail further delays. In instances where we have an equity investment in our tenant’s operations, in addition to the effect on these tenants’ ability to meet their financial obligation to us, our ownership and investment interests may also be negatively impacted.


~~Exhibit~~ ~~Number~~		~~Description~~

Exhibit 101.LAB		XBRL Taxonomy Extension Label Linkbase Document

Exhibit 101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~


~~Exhibit~~ ~~Number~~		~~Description~~

Exhibit 101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

Exhibit 101.LAB		XBRL Taxonomy Extension Label Linkbase Document

Exhibit 101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

51Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


MARYLAND DELAWARE		20-0191742 20-0242069
(State or other jurisdiction of incorporation or organization)		(I. R. S. Employer Identification No.)

1000 URBAN CENTER DRIVE, SUITE 501 BIRMINGHAM, AL		35242
(Address of principal executive offices)		(Zip Code)


Large accelerated filer	☒	~~(Medical~~ (Medical Properties Trust, Inc. only)	Accelerated filer	☐

Non-accelerated filer	☒	~~(MPT~~ (MPT Operating Partnership, L.P. only) ~~(Do~~	Smaller reporting company	☐

		(Do not check if a smaller reporting company)	~~Smaller reporting company~~ Emerging growth company	☐ ☐


	Page
PART I — FINANCIAL INFORMATION		4
Item 1 Financial Statements		4
Medical Properties Trust, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets at ~~June~~September 30, 2017 and December 31, 2016		4
Condensed Consolidated Statements of Net Income for the Three Months and ~~Six~~Nine Months Ended ~~June~~September 30, 2017 and 2016		5
Condensed Consolidated Statements of Comprehensive Income for the Three Months and ~~Six~~Nine Months Ended ~~June~~September 30, 2017 and 2016		6
Condensed Consolidated Statements of Cash Flows for the ~~Six~~Nine Months Ended ~~June~~September 30, 2017 and 2016		7
MPT Operating Partnership, L.P. and Subsidiaries
Condensed Consolidated Balance Sheets at ~~June~~September 30, 2017 and December 31, 2016		8
Condensed Consolidated Statements of Net Income for the Three Months and ~~Six~~Nine Months Ended ~~June~~September 30, 2017 and 2016		9
Condensed Consolidated Statements of Comprehensive Income for the Three Months and ~~Six~~Nine Months Ended ~~June~~September 30, 2017 and 2016		10
Condensed Consolidated Statements of Cash Flows for the ~~Six~~Nine Months Ended ~~June~~September 30, 2017 and 2016		11
Medical Properties Trust, Inc. and MPT Operating Partnership, L.P.
Notes to Condensed Consolidated Financial Statements		12
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations		30
Item 3 Quantitative and Qualitative Disclosures about Market Risk		4241
Item 4 Controls and Procedures		4342
PART II — OTHER INFORMATION		4443
Item 1 Legal Proceedings		4443
Item 1A Risk Factors		4443
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds		4644
Item 3 Defaults Upon Senior Securities		4644
Item 4 Mine Safety Disclosures		4644
Item 5 Other Information		4644
Item 6 Exhibits		47
~~SIGNATURE~~		4945
INDEX TO EXHIBITS		5046
SIGNATURE		47


Property	Commitment		Costs Incurred as of June 30, 2017		Estimated Completion Date
Ernest (Flagstaff)	$	28,067	$	11,351		1Q 2018
Circle (Birmingham)		42,017		7,088		4Q 2018

	$	70,084	$	18,439


Property	Commitment		Costs Incurred as of September 30, 2017		Estimated Completion Date
Ernest (Flagstaff, Arizona)	$	28,067	$	16,619		1Q 2018
Circle (Birmingham, England)		43,221		11,389		1Q 2019

	$	71,288	$	28,008


	For the Three Months				For the Nine Months
	Ended September 30,				Ended September 30,
	2017		2016		2017		2016
Total revenues	$	209,368	$	207,898	$	623,635	$	622,798
Net income	$	102,112	$	107,863	$	311,306	$	307,645
Net income per share/unit — diluted	$	0.28	$	0.30	$	0.85	$	0.84


Exhibit Number		Description

~~4.1(1)~~ 4.1*		~~Eleventh~~Twelfth Supplemental Indenture, dated as of ~~March 24,~~September 21, 2017, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, and Wilmington Trust, National Association, as ~~trustee, and Deutsche Bank Trust Company Americas, as paying agent, registrar and transfer agent.~~trustee.

10.1*		~~IASIS (Project Ignite) Master Agreement, dated as of May 18, 2017, by and among Steward Heath Care System LLC and subsidiaries of MPT Operating Partnerships, L.P.~~

10.2*		Real Property Asset Purchase Agreement, dated as of May 18, 2017, by and among IASIS Healthcare Corporation, as “IASIS”, and subsidiaries of IASIS, as the “Sellers”, and subsidiaries of MPT Operating Partnership, L.P., as the “MPT Parties”.

10.3*		~~Amendment to Master Lease Agreement, dated as of December 31, 2016, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.~~

10.4*		Joinder and Amendment to Master Lease Agreement, dated as of ~~May 1,~~September 29, 2017, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.

10.510.2		Joinder and Amendment to Real Estate Loan Agreement, dated as of ~~May 1, 2017, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.~~

10.6*		~~Amendment to Master Lease Agreement, dated as of May 2,~~September 29, 2017, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.

31.1*		Certification of Chief Executive Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)

31.2*		Certification of Chief Financial Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)

31.3*		Certification of Chief Executive Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)

31.4*		Certification of Chief Financial Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)

32.1**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Medical Properties Trust, Inc.)

32.2**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (MPT Operating Partnership, L.P.)

Exhibit 101.INS		XBRL Instance Document

Exhibit 101.SCH		XBRL Taxonomy Extension Schema Document

Exhibit 101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

Exhibit 101.DEF		XBRL Taxonomy Extension Definition Linkbase Document


~~MEDICAL PROPERTIES TRUST, INC.~~

~~By:~~		~~/s/ J. Kevin Hanna~~
		~~J. Kevin Hanna~~
		~~Vice President, Controller, Assistant Treasurer, and Chief Accounting Officer~~ ~~(Principal Accounting Officer)~~

~~MPT OPERATING PARTNERSHIP, L.P.~~

~~By:~~		~~/s/ J. Kevin Hanna~~
		~~J. Kevin Hanna~~
		~~Vice President, Controller, Assistant~~ ~~Treasurer, and Chief Accounting Officer~~ ~~of the sole member of the general partner~~ ~~of MPT Operating Partnership, L.P.~~ ~~(Principal Accounting Officer)~~


Exhibit Number		Description

~~4.1(1)~~4.1*		~~Eleventh~~Twelfth Supplemental Indenture, dated as of ~~March~~ ~~24,~~September 21, 2017, by and among MPT Operating Partnership, L.P. and MPT Finance Corporation, as issuers, Medical Properties Trust, Inc., as parent and guarantor, and Wilmington Trust, National Association, as ~~trustee, and Deutsche Bank Trust Company Americas, as paying agent, registrar and transfer agent.~~trustee.

10.1*		~~IASIS (Project Ignite) Master Agreement, dated as of May 18, 2017, by and among Steward Heath Care System LLC and subsidiaries of MPT Operating Partnerships, L.P.~~

10.2*		Real Property Asset Purchase Agreement, dated as of May 18, 2017, by and among IASIS Healthcare Corporation, as “IASIS”, and subsidiaries of IASIS, as the “Sellers”, and subsidiaries of MPT Operating Partnership, L.P., as the “MPT Parties”.

10.3*		~~Amendment to Master Lease Agreement, dated as of December 31, 2016, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.~~

10.4*		Joinder and Amendment to Master Lease Agreement, dated as of ~~May 1,~~September 29, 2017, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.

10.510.2		Joinder and Amendment to Real Estate Loan Agreement, dated as of ~~May 1, 2017, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.~~

10.6*		~~Amendment to Master Lease Agreement, dated as of May 2,~~September 29, 2017, by and among certain Affiliates of MPT Operating Partnership, L.P. and certain Affiliates of Steward Health Care System LLC.

31.1*		Certification of Chief Executive Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)

31.2*		Certification of Chief Financial Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (Medical Properties Trust, Inc.)

31.3*		Certification of Chief Executive Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)

31.4*		Certification of Chief Financial Officer pursuant to Rule13a-14(a) under the Securities Exchange Act of 1934. (MPT Operating Partnership, L.P.)

32.1**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Medical Properties Trust, Inc.)

32.2**		Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (MPT Operating Partnership, L.P.)

Exhibit 101.INS		XBRL Instance Document

Exhibit 101.SCH		XBRL Taxonomy Extension Schema Document

Exhibit 101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document


By:		/s/ J. Kevin Hanna
		J. Kevin Hanna
		Vice President, Controller, Assistant Treasurer, and Chief Accounting Officer (Principal Accounting Officer)


By:		/s/ J. Kevin Hanna
		J. Kevin Hanna
		Vice President, Controller, Assistant
		Treasurer, and Chief Accounting Officer
		of the sole member of the general partner
		of MPT Operating Partnership, L.P.
		(Principal Accounting Officer)